

# Q3 2022

---

QUARTERLY FINANCIAL REPORT

# TABLE OF CONTENTS

3 Fresenius Group figures at a glance

4 Shareholder information

**6 Management Report**

- 6 Strategy and goals
- 7 Healthcare industry
- 9 Results of operations, financial position, assets and liabilities
  - 9 Sales
  - 10 Earnings
  - 11 Reconciliation
  - 12 Investments
  - 12 Cash flow
  - 13 Asset and liability structure

- 14 Business segments
  - 14 Fresenius Medical Care
  - 16 Fresenius Kabi
  - 18 Fresenius Helios
  - 20 Fresenius Vamed
- 22 Employees
- 22 Changes to the Supervisory Board
- 22 Changes to the Management Board
- 23 Research and development
- 23 Rating
- 24 Opportunities and risk report
- 24 Subsequent events
- 25 Outlook 2022
- 28 Reconciliation tables
- 32 Estimated COVID-19 effects

**33 Consolidated financial statements**

- 33 Consolidated statement of income
- 34 Consolidated statement of comprehensive income
- 35 Consolidated statement of financial position
- 36 Consolidated statement of cash flows
- 38 Consolidated statement of changes in equity
- 40 Consolidated segment reporting first three quarters of 2022
- 41 Consolidated segment reporting third quarter of 2022

42 Notes

68 Financial Calendar

## FRESENIUS GROUP FIGURES AT A GLANCE

Fresenius is a global healthcare group providing products and services for dialysis, hospitals, and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other healthcare facilities. In 2021, Group sales were €37.5 billion. As of September 30, 2022, more than 300,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

### SALES AND EARNINGS

€ in millions	Q3/2022	Growth	Growth in constant currency	Q1-3/2022	Growth	Growth in constant currency
Sales	10,459	12%	5%	30,197	10%	4%
EBIT <sup>1</sup>	949	-9%	-17%	2,952	-4%	-10%
Net income <sup>1,2</sup>	371	-15%	-22%/-19% <sup>3</sup>	1,284	-5%	-10%/-8% <sup>3</sup>

### BALANCE SHEET

€ in millions	Sep. 30, 2022	Dec. 31, 2021	Change
Total assets	80,328	71,962	12%
Equity <sup>4</sup>	34,156	29,288	17%
Equity ratio <sup>4</sup>	42.5%	40.7%	
Net debt/EBITDA <sup>1,5</sup>	3.74	3.51	

### PROFITABILITY

	Q3/2022	Q3/2021	Q1-3/2022	Q1-3/2021
EBIT margin <sup>1</sup>	9.1%	11.2%	9.8%	11.2%
Return on equity after tax (ROE) <sup>1,2,6</sup>			8.4%	9.8%
Return on operating assets (ROOA) <sup>1,6</sup>			5.7%	6.5%
Return on invested capital (ROIC) <sup>1,6</sup>			5.1%	5.9%

<sup>1</sup> Before special items, Q1/22 restated following remeasurement Humacyte investment

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>3</sup> Excluding Ivenix and mAbxience acquisition

<sup>4</sup> Including noncontrolling interests

<sup>5</sup> At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures


<sup>6</sup> 2021: annual return FY/21

# SHAREHOLDER INFORMATION

The ongoing war in Ukraine and related events continue to cause additional upward pressure on global inflation during the third quarter. Overall, the DAX lost 24% in the first nine months, while the Fresenius share closed 38% lower at €21.95.

RELATIVE SHARE PRICE PERFORMANCE VS. DAX

31.12.2021 = 100%



## KEY DATA OF THE FRESENIUS SHARE

	Q1-3/2022	2021	Growth
Number of shares (Sep. 30/Dec. 31)	563,237,277	558,502,143	1%
Stock exchange quotation <sup>1</sup> in €			
High	37.88	47.44	-20%
Low	21.22	33.45	-37%
Period-end quotation closing price in €	21.95	35.40	-38%
Ø Trading volume (number of shares per trading day)	1,596,949	1,405,536	14%
Market capitalization <sup>2</sup> in million € (Sep. 30/Dec. 31)	12,363	19,771	-37%

<sup>1</sup> Xetra closing price on the Frankfurt Stock Exchange

<sup>2</sup> Total number of ordinary shares multiplied by the respective Xetra period-end quotation on the Frankfurt Stock Exchange

## DEVELOPMENT IN THE THIRD QUARTER 2022


The war in Ukraine continues to cause tremendous human and economic suffering and aggravates inflationary pressures on the global economy. In addition, supply-demand imbalances, rising food and energy prices and broader price pressures are fueling global inflation, deteriorating uncertainty about the economic outlook.

Overall, current ECB forecasts assume an average annual real GDP growth rate of 3.1% in the euro zone. This equates to an increase of 0.3 percentage points compared to previous estimations. As of November 2, 2022 the ECB raises the key interest rate in the euro zone by a further 75 basis points to 2.0%.


The Federal Reserve's latest forecast projects the U.S. economy to grow by 1.7% in 2022. In September, the U.S. Federal Reserve raised its main interest rate by a further 75 basis points to 3.25%.

Within this economic environment, the DAX decreased by 24% in the first nine months of 2022 to 12,784 points. The Fresenius share lost 38% and closed at €21.95 on September 30, 2022.

## SHAREHOLDER STRUCTURE BY INVESTORS



## SHAREHOLDER STRUCTURE BY REGION



## ANALYST RECOMMENDATIONS



## SHAREHOLDER STRUCTURE

The charts opposite show the shareholder structure at the end of the first half of 2022. The Else Kröner-Fresenius-Stiftung was the largest shareholder of Fresenius SE & Co. KGaA, with 26.96% of the shares. According to notifications pursuant to the German Securities Trading Act (WpHG), BlackRock, Inc. held below 5% and Harris Associates L.P. above 3% of the shares. For further information on notifications, please visit [www.fresenius.com/shareholder-structure](http://www.fresenius.com/shareholder-structure).

As of June 30, 2022, a shareholder survey identified the ownership of about 96% of our subscribed capital. A total of over 600 institutional investors held about 340 million shares or 60% (December 31, 2021: 61%) of the subscribed capital; 50.6 million (December 31, 2021: 48.1 million) shares were identified as retail holdings. Unchanged from the previous year, the 10 largest investors held about 20% of the share capital. Our shares were mostly held by investors in Germany, the United States, and the United Kingdom.

## ANALYST RECOMMENDATIONS

The recommendations published by financial analysts are an important guide for institutional and private investors when making investment decisions. According to our survey, as of November 2, 2022, we were rated with 9 "buy", 9 "hold", and no "sell" recommendations. The list of banks that provide regular analyst coverage of Fresenius and their latest recommendations can be found at [www.fresenius.com/analysts-and-consensus](http://www.fresenius.com/analysts-and-consensus).

## SUSTAINABILITY PROGRAM

For Fresenius, sustainability is an integral part of its business model. The company is working to establish global sustainability standards and continuously improve its own sustainability performance.

Fresenius has set a climate target for the Group complementing its existing sustainability targets and programs. The company aims to be climate neutral by 2040 and to reduce 50% of absolute scope 1 and scope 2 emissions by 2030 compared to 2020 levels. Fresenius will continuously assess scope 3 emission impacts for inclusion in our targets. Business segment specialists develop concepts and measures to achieve the climate target in a Group-wide project.

The Fresenius Group Sustainability Board (GSB) has held four meetings so far in 2022 to discuss the implementation of regulatory requirements, in particular the EU taxonomy and the Due Diligence Act, as well as the EU Corporate Sustainability Reporting Directive (CSRD). Furthermore, the quarterly reporting of the ESG KPIs included in the Management Board compensation system was advanced. The business segments have also begun conducting the first Group-wide employee engagement survey in Q3.

# INTERIM MANAGEMENT REPORT

Fresenius with weak third quarter driven by ongoing challenging macroeconomic environment  
– FY/22 guidance revised – Charting a new course for Fresenius

- ▶ **Healthy organic sales growth and ongoing margin pressure**
- ▶ **Fresenius Medical Care's business development impacted by delayed effects from improvements in North American Services business in challenging environment**
- ▶ **Fresenius Kabi with healthy sales growth and sequential improvement**
- ▶ **Fresenius Helios with strong organic sales growth, solid EBIT in line with usual third quarter seasonality**
- ▶ **Fresenius Vamed impacted by macroeconomic headwinds and COVID-19**

## STRATEGY AND GOALS

Our goal is to expand Fresenius' position as a leading global provider of products, services, and therapies for critically and chronically ill people.

Fresenius develops innovative, affordable, and profitable medical solutions in line with megatrends of health and demographics. What drives us to achieve top performance every day is our mission: we improve people's lives by providing high-quality and affordable healthcare. Consequently, Fresenius' business decisions are guided by this mission. At the same time, we want to grow profitably and use our capital efficiently.

## COST AND EFFICIENCY PROGRAM

In 2021, Fresenius initiated a cost and efficiency program to sustainably enhance profitability.

Through implementation of initiatives, Fresenius expects cost savings of at least €150 million p.a. after tax and minority interest in 2023. For the years thereafter, a further significant increase in sustainable cost savings is expected. The savings will be achieved by all four business segments and the corporate center.

Fresenius anticipates that achieving these sustainable efficiency improvements will require up-front expenses of more than €200 million in 2022 and further expenses of around €100 million in 2023, in each case after taxes and minority interest. No further significant expenses are expected thereafter. In line with previous practice, these expenses are classified as special items (see also reconciliation tables on page 28 onwards).

## FME25

With a significantly simplified future structure of two global operating segments – Care Enablement and Care Delivery – Fresenius Medical Care orients its operating model along the relevant future value drivers.

Based on the implementation of the new global operating model, Fresenius Medical Care assumes to reduce its annual cost base by €500 million by the end of 2025.

Around 50% of these savings are expected to be realized by 2023. Around 80% of the anticipated one-time investments in FME25, amounting to approximately €450 – 500 million, are expected to be made by the end of 2023. The investments will be treated as a special item.

## VISION 2026

Fresenius Kabi has developed a strategic plan to transform the company for the next decade. By doing so, Fresenius Kabi enhances its presence and to spur growth, both in terms of top line and ultimately margin expansion. The strategy “3+1” identifies focus areas that are underpinned by structural growth drivers within the healthcare industry. Given the sustainable value potential and the company’s already strong market position, Fresenius Kabi will continue to focus on products and services for critically and chronically ill patients. Within this clear direction, Fresenius Kabi has defined three growth vectors:

- ▶ the broadening of our biopharmaceutical offering,
- ▶ further roll-out of clinical nutrition,
- ▶ expansion in the MedTech area.

The focus will be on further developing the portfolio to capitalize on key market and industry trends in order to capture future growth opportunities. In parallel, Fresenius Kabi will continue to build resilience in its volume-driven IV business.

Furthermore, Fresenius Kabi will improve its global competitiveness and the effectiveness of its organization; a first step was to align the organization with the product areas, in line with the growth strategy.

In the new organizational structure, the business units and the regions will be given more accountability to support Fresenius Kabi’s growth targets. At the same time, the interfaces within the company will be streamlined to foster collaboration. The new organization was implemented as of January 2022.

## HEALTHCARE INDUSTRY

The healthcare sector is one of the world’s largest industries and we are convinced that it shows excellent growth opportunities.

The main **growth factors** are:

- ▶ rising medical needs deriving from aging populations,
- ▶ the growing number of chronically ill and multimorbid patients,
- ▶ stronger demand for innovative products and therapies,
- ▶ advances in medical technology,
- ▶ the growing health consciousness, which increases the demand for healthcare services and facilities, and
- ▶ the increasing demand for digital health services for patients.

In the **emerging countries, additional drivers** are:

- ▶ expanding availability and correspondingly greater demand for basic healthcare, and
- ▶ increasing national incomes and hence higher spending on healthcare.

Healthcare structures are being reviewed and cost-cutting potential identified in order to contain the steadily rising **healthcare expenditures**. However, such measures cannot compensate for the cost pressure. Market-based elements are increasingly being introduced into the healthcare system to create incentives for cost- and quality-conscious behavior. Overall treatment costs will be reduced through improved quality standards.

In addition, ever-greater importance is being placed on disease prevention and innovative reimbursement models linked to treatment quality standards.

In addition, increasing digitization in healthcare can contribute to improved cost efficiency and patient care.

The industry-specific framework for the operating business of the Fresenius Group remained essentially unchanged in the reporting period.

### External factors

The COVID-19 pandemic has a significant impact on the economic environment of the Fresenius Group. We demonstrated our special responsibility as part of the healthcare system even under the difficult circumstances of the COVID-19 pandemic.

Russia's war against the Ukraine, will continue to have a significant negative impact on our net assets, financial position, and results of operations. While the direct and indirect impact of the war is difficult to predict at the present time, the current, significant macroeconomic inflationary environment, including materially increasing energy prices, has resulted in and could continue to lead to, amongst other consequences, material increases in costs for energy, supplies, and transportation. Furthermore, supply chain disruptions as well as labor shortages and related increases in labor costs present risks which adversely effect our business operations. Further explanations can be found in the opportunity and risk report.

The legal framework for the operating business of the Fresenius Group remained essentially unchanged.

We carefully monitor and evaluate country-specific, political, legal, and financial conditions.



## RESULTS OF OPERATIONS, FINANCIAL POSITION, ASSETS AND LIABILITIES

### SALES

Group sales increased by 12% (5% in constant currency) to €10,459 million (Q3/21: €9,324 million). Organic growth was 4%. Acquisitions/divestitures contributed net 1% to growth. Currency translation increased sales growth by 7%. Excluding estimated COVID-19 effects<sup>1</sup>, Group sales growth would have been 4% to 5% in constant currency (Q3/21: 7% to 8%).

In Q1-3/22, Group sales increased by 10% (4% in constant currency) to €30,197 million (Q1-3/21: €27,554 million). Organic growth was 3%. Acquisitions/divestitures contributed net 1% to growth. Currency translation increased sales growth by 6%. Excluding estimated COVID-19 effects<sup>1</sup>, Group sales growth would have been 3% to 4% in constant currency (Q1-3/21: 5% to 6%).

### SALES BY REGION

€ in millions	Q3/2022	Q3/2021	Growth	Currency translation effects	Growth at constant rates	Organic sales growth	Acquisitions	Divestitures/ Others	% of total sales
North America	4,226	3,672	15%	16%	-1%	-2%	1%	0%	40%
Europe	4,367	4,098	7%	0%	7%	6%	1%	0%	42%
Asia-Pacific	1,097	986	11%	7%	4%	4%	0%	0%	11%
Latin America	632	461	37%	4%	33%	29%	4%	0%	6%
Africa	137	107	28%	0%	28%	28%	0%	0%	1%
<b>Total</b>	<b>10,459</b>	<b>9,324</b>	<b>12%</b>	<b>7%</b>	<b>5%</b>	<b>4%</b>	<b>1%</b>	<b>0%</b>	<b>100%</b>

€ in millions	Q1-3/2022	Q1-3/2021	Growth	Currency translation effects	Growth at constant rates	Organic sales growth	Acquisitions	Divestitures/ Others	% of total sales
North America	11,901	10,601	12%	12%	0%	-1%	1%	0%	40%
Europe	13,178	12,438	6%	0%	6%	5%	1%	0%	44%
Asia-Pacific	3,105	2,867	8%	6%	2%	2%	0%	0%	10%
Latin America	1,635	1,336	22%	4%	18%	15%	3%	0%	5%
Africa	378	312	21%	1%	20%	20%	0%	0%	1%
<b>Total</b>	<b>30,197</b>	<b>27,554</b>	<b>10%</b>	<b>6%</b>	<b>4%</b>	<b>3%</b>	<b>1%</b>	<b>0%</b>	<b>100%</b>

### SALES BY BUSINESS SEGMENT

€ in millions	Q3/2022	Q3/2021	Growth	Currency translation effects	Growth at constant rates	Organic sales growth	Acquisitions	Divestitures/ Others	% of total sales <sup>2</sup>
Fresenius Medical Care	5,096	4,442	15%	12%	3%	2%	1%	0%	48%
Fresenius Kabi	2,071	1,854	12%	8%	4%	3%	1%	0%	20%
Fresenius Helios	2,829	2,622	8%	1%	7%	6%	2%	-1%	27%
Fresenius Vamed	572	516	11%	1%	10%	10%	1%	-1%	5%
<b>Total</b>	<b>10,459</b>	<b>9,324</b>	<b>12%</b>	<b>7%</b>	<b>5%</b>	<b>4%</b>	<b>1%</b>	<b>0%</b>	<b>100%</b>

€ in millions	Q1-3/2022	Q1-3/2021	Growth	Currency translation effects	Growth at constant rates	Organic sales growth	Acquisitions	Divestitures/ Others	% of total sales <sup>2</sup>
Fresenius Medical Care	14,401	12,972	11%	9%	2%	1%	1%	0%	47%
Fresenius Kabi	5,814	5,370	8%	6%	2%	2%	0%	0%	19%
Fresenius Helios	8,685	8,009	8%	0%	8%	6%	2%	0%	29%
Fresenius Vamed	1,647	1,549	6%	0%	6%	6%	1%	-1%	5%
<b>Total</b>	<b>30,197</b>	<b>27,554</b>	<b>10%</b>	<b>6%</b>	<b>4%</b>	<b>3%</b>	<b>1%</b>	<b>0%</b>	<b>100%</b>

<sup>1</sup> For estimated COVID-19 effects please see tables on page 28 onwards.

<sup>2</sup> The following description of sales relates to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

## EARNINGS

Group **EBITDA** before special items decreased by 2% (-10% in constant currency) to €1,662 million (Q3/21<sup>2</sup>: €1,703 million). Reported Group EBITDA was €1,658 million (Q3/21: €1,667 million).

In Q1-3/22, Group **EBITDA** before special items remained nearly unchanged (-6% in constant currency) at €5,006 million (Q1-3/21<sup>2</sup>: €5,008 million). Reported Group EBITDA was €4,781 million (Q1-3/21: €4,957 million).

Group **EBIT** before special items decreased by 9% (-17% in constant currency) to €949 million (Q3/21<sup>2</sup>: €1,044 million). The decrease was mainly driven by higher labor costs at Fresenius Medical Care in the U.S., general cost inflation, revaluation of contract assets in the international service and project business at Fresenius Vamed as well as higher costs in the Corporate segment. The EBIT margin before special items was 9.1% (Q3/21<sup>2</sup>: 11.2%). Reported Group EBIT was €887 million (Q3/21: €1,008 million).

In Q1-3/22, Group **EBIT** before special items decreased by 4% (-10% in constant currency) to €2,952 million (Q1-3/21<sup>2</sup>: €3,086 million). The EBIT margin before special items was 9.8% (Q1-3/21<sup>2</sup>: 11.2%). Reported Group EBIT was €2,634 million (Q1-3/21: €3,035 million).

## EARNINGS

€ in millions	Q3/2022	Q3/2021	Growth	Q1-3/2022	Q1-3/2021	Growth
Sales	10,459	9,324	12%	30,197	27,554	10%
Costs of sales	-7,754	-6,801	-14%	-22,256	-19,955	-12%
<b>Gross profit</b>	<b>2,705</b>	<b>2,523</b>	<b>7%</b>	<b>7,941</b>	<b>7,599</b>	<b>5%</b>
Selling, general and administrative expenses	-1,610	-1,300	-24%	-4,717	-3,966	-19%
Research and development expenses	-209	-215	3%	-590	-598	1%
<b>Operating income (EBIT)</b>	<b>887</b>	<b>1,008</b>	<b>-12%</b>	<b>2,634</b>	<b>3,035</b>	<b>-13%</b>
Interest result	-141	-126	-12%	-375	-384	2%
<b>Financial result</b>	<b>-141</b>	<b>-126</b>	<b>-12%</b>	<b>-375</b>	<b>-384</b>	<b>2%</b>
<b>Income before income taxes</b>	<b>746</b>	<b>882</b>	<b>-15%</b>	<b>2,259</b>	<b>2,651</b>	<b>-15%</b>
Income taxes	-194	-201	3%	-545	-591	8%
<b>Net income</b>	<b>551</b>	<b>681</b>	<b>-19%</b>	<b>1,714</b>	<b>2,060</b>	<b>-17%</b>
Noncontrolling interests	-230	-268	14%	-597	-741	19%
<b>Net income attributable to Fresenius SE &amp; Co. KGaA<sup>1,2</sup></b>	<b>371</b>	<b>435</b>	<b>-15%</b>	<b>1,284</b>	<b>1,346</b>	<b>-5%</b>
Net income attributable to Fresenius SE & Co. KGaA <sup>1</sup>	321	413	-22%	1,117	1,319	-15%
<b>Earnings per ordinary share (€)<sup>1,2</sup></b>	<b>0.66</b>	<b>0.78</b>	<b>-15%</b>	<b>2.29</b>	<b>2.41</b>	<b>-5%</b>
Fully diluted earnings per ordinary share (€) <sup>1,2</sup>	0.66	0.78	-15%	2.29	2.41	-5%
<b>Earnings per ordinary share (€)<sup>1</sup></b>	<b>0.57</b>	<b>0.74</b>	<b>-22%</b>	<b>1.99</b>	<b>2.36</b>	<b>-15%</b>
Fully diluted earnings per ordinary share (€) <sup>1</sup>	0.57	0.74	-22%	1.99	2.36	-15%
Average number of shares	563,237,277	558,448,118	1%	560,606,647	557,920,123	0%
EBITDA <sup>2</sup>	1,662	1,703	-2%	5,006	5,008	0%
Depreciation and amortization <sup>2</sup>	713	659	8%	2,054	1,922	7%
EBIT <sup>2</sup>	949	1,044	-9%	2,952	3,086	-4%
EBITDA margin <sup>2</sup>	15.9%	18.3%		16.6%	18.2%	
EBIT margin <sup>2</sup>	9.1%	11.2%		9.8%	11.2%	

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>2</sup> Before special items

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

Group **net interest** before special items was -€141 million (Q3/21<sup>1</sup>: -€126 million) mainly due to currency translation effects and overall higher interest rates. Reported Group net interest decreased to -€141 million (Q3/21: -€126 million).

In Q1-3/22, Group **net interest** before special items improved to -€376 million (Q1-3/21<sup>1</sup>: -€384 million). Reported Group net interest improved to -€375 million (Q1-3/21: -€384 million).

Group **tax rate** before special items was 25.0% (Q3/21<sup>1</sup>: 22.9%) mainly due to an increase in the proportionate share of non-tax-deductible expenses compared to taxable income at Fresenius Medical Care. Reported Group tax rate was 26.1% (Q3/21: 22.8%).

In Q1-3/22, Group **tax rate** before special items was 23.5% (Q1-3/21<sup>1</sup>: 22.4%) while the reported Group tax rate was 24.1% (Q1-3/21: 22.3%).

**Noncontrolling interests** before special items were -€235 million (Q3/21<sup>1</sup>: -€273 million) of which 90% were attributable to the noncontrolling interests in Fresenius Medical Care. Reported noncontrolling interests were -€230 million (Q3/21: -€268 million).

In Q1-3/22, **Noncontrolling interests** before special items were -€686 million (Q1-3/21<sup>1</sup>: -€751 million) of which 89% were attributable to the noncontrolling interests in Fresenius Medical Care. Reported noncontrolling interests were -€597 million (Q1-3/21: -€741 million).

Group **net income**<sup>2</sup> before special items decreased by 15% (-22%/-19%<sup>3</sup> in constant currency) to €371 million (Q3/21<sup>1</sup>: €435 million). The decrease was mainly driven by higher labor costs at Fresenius Medical Care in the U.S., general cost inflation, revaluation of contract assets in the international service and project business at Fresenius Vamed as well as higher costs in the Corporate segment. Moreover, increased interest expenses and a higher tax rate had a negative effect on Group net income. Excluding estimated COVID-19 effects<sup>4</sup>, Group net income<sup>2</sup> before special items was -26% to -22% in constant currency (Q3/21: 12% to 16%). Reported Group net income<sup>2</sup> decreased to €321 million (Q3/21: €413 million).

In Q1-3/22, Group **net income**<sup>2</sup> before special items decreased by 5% (-10%/-8%<sup>3</sup> in constant currency) to €1,284 million (Q1-3/21<sup>1</sup>: €1,346 million). Excluding estimated COVID-19 effects<sup>4</sup>, Group net income<sup>2</sup> before special items was -15% to -11% in constant currency (Q1-3/21: 7% to 11%). Reported Group net income<sup>2</sup> decreased to €1,117 million (Q1-3/21: €1,319 million).

**Earnings per share**<sup>2</sup> before special items decreased by 15% (-22% in constant currency) to €0.66 (Q3/21: €0.78). Reported earnings per share<sup>2</sup> were €0.57 (Q3/21: €0.74).

In Q1-3/22, **earnings per share**<sup>2</sup> before special items decreased by 5% (-10% in constant currency) to €2.29 (Q1-3/21: €2.41). Reported earnings per share<sup>2</sup> were €1.99 (Q1-3/21: €2.36).

## RECONCILIATION

To present the underlying operational business performance and in order to compare the results with the scope of the guidance provided for fiscal year 2022, key figures are presented before special items.

Consolidated results for Q3 and Q1-3/2022 as well as Q3 and Q1-3/2021 include special items.

These concern:

- ▶ revaluations of biosimilars contingent purchase price liabilities
- ▶ expenses associated with the Fresenius cost and efficiency program (including costs related to FME25 program); cf. further explanations in the section "Strategy and Goals" on page 6
- ▶ impacts related to the war in Ukraine
- ▶ transaction costs mAbxience, Ivenix
- ▶ hyperinflation Turkey: Due to the current significant inflation, the deterioration of the economic situation and foreign exchange controls in Turkey, IAS 29 "Financial Reporting in Hyperinflationary Economies" is applied for the interim reporting period. The corresponding effects on profit or loss have therefore been adjusted
- ▶ retroactive duties
- ▶ remeasurement Humacyte investment
- ▶ Net Gain related to InterWell Health

The special items shown within the reconciliation tables are reported in the "Corporate" segment. For a detailed overview of special items please see the reconciliation tables from page 28 onwards.

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>3</sup> Excluding Ivenix and mAbxience acquisition

<sup>4</sup> For estimated COVID-19 effects please see table on page 32.

## INVESTMENTS

Spending on **property, plant and equipment** was €416 million corresponding to 4% of sales (Q3/21: €449 million; 5% of sales). These investments served primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals and day clinics.

In Q1-3/22, spending on **property, plant and equipment** was €1,173 million corresponding to 4% of sales (Q1-3/21: €1,342 million; 5% of sales).

Total **acquisition spending** was €502 million (Q3/21: €167 million), mainly for the majority stake in mAbxience by Fresenius Kabi.

In Q1-3/22, total **acquisition spending** was €955 million (Q1-3/21: €807 million).

## CASH FLOW

Group **operating cash flow** increased to €1,256 million (Q3/21: €1,226 million) with a margin of 12.0% (Q3/21: 13.1%). **Free cash flow before acquisitions and dividends** increased to €876 million (Q3/21: €793 million). **Free cash flow after acquisitions and dividends** decreased to €388 million (Q3/21: €594 million).

In Q1-3/22, Group **operating cash flow** decreased to €2,374 million (Q1-3/21: €3,329 million) with a margin of 7.9% (Q1-3/21: 12.1%). **Free cash flow before acquisitions and dividends** decreased to €1,202 million (Q1-3/21: €1,986 million). **Free cash flow after acquisitions and dividends** decreased to -€406 million (Q1-3/21: €352 million).

## INVESTMENTS/ACQUISITIONS BY BUSINESS SEGMENT

€ in millions	Q1-3/2022	Q1-3/2021	Thereof property, plant and equipment	Thereof acquisitions	Growth	% of total
Fresenius Medical Care	631	954	495	136	-34%	30%
Fresenius Kabi	1,031	347	308	723	197%	49%
Fresenius Helios	411	779	330	81	-47%	19%
Fresenius Vamed	46	58	31	15	-21%	2%
Corporate	9	11	9	-	-18%	0%
<b>Total</b>	<b>2,128</b>	<b>2,149</b>	<b>1,173</b>	<b>955</b>	<b>-1%</b>	<b>100%</b>

## CASH FLOW STATEMENT (SUMMARY)

€ in millions	Q3/2022	Q3/2021	Growth	Q1-3/2022	Q1-3/2021	Growth
Net income	551	681	-19%	1,714	2,060	-17%
Depreciation and amortization	771	659	17%	2,147	1,922	12%
Change working capital and others	-66	-114	42%	-1,487	-653	-128%
<b>Operating Cash flow</b>	<b>1,256</b>	<b>1,226</b>	<b>2%</b>	<b>2,374</b>	<b>3,329</b>	<b>-29%</b>
Capital expenditure, net	-380	-433	12%	-1,172	-1,343	13%
<b>Cash flow before acquisitions and dividends</b>	<b>876</b>	<b>793</b>	<b>10%</b>	<b>1,202</b>	<b>1,986</b>	<b>-39%</b>
Cash used for acquisitions/proceeds from divestitures	-428	-124	--	-791	-643	-23%
Dividends paid	-60	-75	20%	-817	-991	18%
<b>Free cash flow after acquisitions and dividends</b>	<b>388</b>	<b>594</b>	<b>-35%</b>	<b>-406</b>	<b>352</b>	<b>--</b>
Cash provided by/used for financing activities	-439	-492	11%	-350	96	--
Effect of exchange rates on change in cash and cash equivalents	50	61	-18%	120	128	-6%
<b>Net change in cash and cash equivalents</b>	<b>-1</b>	<b>163</b>	<b>-101%</b>	<b>-636</b>	<b>576</b>	<b>--</b>

## ASSET AND LIABILITY STRUCTURE

Group **total assets** increased by 12% (4% in constant currency) to €80,328 million (Dec. 31, 2021: €71,962 million) given currency translation effects, acquisitions and the expansion of business activities. **Current assets** increased by 11% (6% in constant currency) to €19,443 million (Dec. 31, 2021: €17,461 million), mainly driven by the increase of trade accounts receivables and inventories. **Non-current assets** increased by 12% (4% in constant currency) to €60,885 million (Dec. 31, 2021: €54,501 million).

Total **shareholders' equity** increased by 17% (6% in constant currency) to €34,156 million (Dec. 31, 2021: €29,288 million). The equity ratio was 42.5% (Dec. 31, 2021: 40.7%).

Group **debt** increased by 5% (1% in constant currency) at €28,607 million (Dec. 31, 2021: €27,155 million). Group **net debt** increased by 9% (4% in constant currency) to €26,479 million (Dec. 31, 2021: €24,391 million).

As of September 30, 2022, the net debt/EBITDA ratio was 3.74x<sup>1,2</sup> (Dec. 31, 2021: 3.51x<sup>1,2</sup>) mainly driven by lower EBITDA contribution as well as acquisition spending. The net debt/EBITDA ratio as of September 30, 2022 excluding the closed acquisition of Ivenix and the completed acquisition of a majority stake in mAbxience was 3.64x<sup>1,2</sup>.

## BALANCE SHEET

€ in millions

	Sep. 30, 2022	Dec. 31, 2021	Change
<b>Assets</b>			
<b>Current assets</b>	<b>19,443</b>	<b>17,461</b>	<b>11%</b>
thereof trade accounts receivables	7,977	7,045	13%
thereof inventories	4,999	4,218	19%
thereof cash and cash equivalents	2,128	2,764	-23%
<b>Non-current assets</b>	<b>60,885</b>	<b>54,501</b>	<b>12%</b>
thereof property, plant and equipment	13,251	12,569	5%
thereof goodwill and other intangible assets	37,849	32,774	15%
thereof right-of-use-assets	6,376	6,014	6%
<b>Total assets</b>	<b>80,328</b>	<b>71,962</b>	<b>12%</b>
<b>Liabilities and shareholders' equity</b>			
<b>Liabilities</b>	<b>46,172</b>	<b>42,674</b>	<b>8%</b>
thereof trade accounts payable	1,926	2,039	-6%
thereof accruals and other short-term liabilities	11,429	10,594	8%
thereof debt	28,607	27,155	5%
<i>thereof lease liabilities</i>	<i>7,041</i>	<i>6,590</i>	<i>7%</i>
<b>Noncontrolling interests</b>	<b>12,774</b>	<b>10,290</b>	<b>24%</b>
<b>Total Fresenius SE&amp;Co. KGaA shareholders' equity</b>	<b>21,382</b>	<b>18,998</b>	<b>13%</b>
<b>Total shareholders' equity</b>	<b>34,156</b>	<b>29,288</b>	<b>17%</b>
<b>Total liabilities and shareholders' equity</b>	<b>80,328</b>	<b>71,962</b>	<b>12%</b>

<sup>1</sup> At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures

<sup>2</sup> Before special items

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

## BUSINESS SEGMENTS

### FRESENIUS MEDICAL CARE

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of September 30, 2022, Fresenius Medical Care was treating 344,593 patients in 4,153 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.

€ in millions	Q3/2022	Q3/2021	Growth	Growth in constant currency	Q1-3/2022	Q1-3/2021	Growth	Growth in constant currency
Sales	5,096	4,441	15%	3%	14,401	12,972	11%	2%
EBITDA <sup>1</sup>	914	916	0%	-11%	2,600	2,610	0%	-8%
EBIT <sup>1</sup>	470	513	-8%	-18%	1,322	1,423	-7%	-14%
Net income <sup>1,2</sup>	231	280	-17%	-25%	660	756	-13%	-18%
Employees (Sep. 30/Dec. 31)					130,295	130,251	0%	

- ▶ Business development continues to be strongly impacted by highly uncertain macroeconomic environment driving wage and general cost inflation in all reporting segments
- ▶ Impacts of improvements in North American Health Care Services operations delayed
- ▶ COVID-19-related excess mortality in line with expectations
- ▶ Important step in value-based care achieved with closing of InterWell Health merger

**Sales** increased by 15% (3% in constant currency) to €5,096 million (Q3/21: €4,441 million). Organic growth was 2%. Currency translation increased sales growth by 12%.

In Q1-3/22, **sales** increased by 11% (2% in constant currency) to €14,401 million (Q1-3/21: €12,972 million). Organic growth was 1%. Currency translation increased sales growth by 9%.

**EBIT** decreased by 7% (-17% in constant currency) to €472 million (Q3/21: €505 million) resulting in a margin of 9.3% (Q3/21: 11.4%). EBIT before special items decreased by 8% (-18% in constant currency) to €470 million (Q3/21: €513 million), resulting in a margin<sup>1</sup> of 9.2% (Q3/21: 11.6%). At constant currency, the decline was mainly due to higher labor costs as well as inflationary and supply chain cost increases. This was partially offset by €80 million (Q3 2021: €0.3 million) of Provider Relief Funding from the U.S. government to compensate for certain COVID-19-related costs.

In Q1-3/22, **EBIT** decreased by 17% (-24% in constant currency) to €1,160 million (Q1-3/21: €1,403 million) resulting in a margin of 8.1% (Q1-3/21: 10.8%). EBIT before special items decreased by 7% (-14% in constant currency) to €1,322 million (Q1-3/21: €1,423 million), resulting in a margin<sup>1</sup> of 9.2% (Q1-3/21: 11.0%).

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

**Net income**<sup>1</sup> decreased by 16% (-24% in constant currency) to €230 million (Q3/21: €273 million). Net income<sup>1</sup> before special items decreased by 17% (-25% in constant currency) to €231 million (Q3/21: €280 million). Besides the above-mentioned effects on operating income, the constant currency decline was mainly due to an increase in the proportionate share of non-tax-deductible expenses compared to taxable income.

In Q1-3/22, **net income**<sup>1</sup> decreased by 28% (-34% in constant currency) to €535 million (Q1-3/21: €741 million). Net income<sup>1</sup> before special items decreased by 13% (-18% in constant currency) to €660 million (Q1-3/21: €756 million).

**Operating cash flow** was €658 million (Q3/21: €692 million) with a margin of 12.9% (Q3/21: 15.6%). The decrease was mainly due to lower net income.

In Q1-3/22, **operating cash flow** was €1,568 million (Q1-3/21: €1,820 million) with a margin of 10.9% (Q1-3/21: 14.0%).

Based on the delayed impacts of improvements in North American Health Care Services operations, the continuously challenging and uncertain macroeconomic environment, and the results for the third quarter, which had a more pronounced support by one-time effects, Fresenius Medical Care, as a matter of caution, extends its 2022 guidance range for net income<sup>1,3</sup> decline from a high-teens to a high-teens to mid-twenties percentage range. The Company confirms its target for revenue<sup>2</sup> to grow at a low single digit percentage rate in full year 2022. Revenue and net income guidance are both on a constant currency basis and excluding special items<sup>4</sup>.

For further information, please see Fresenius Medical Care's press release at [www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com).

### InterWell Health merger closed

With the closing of the three-way merger of Fresenius Health Partners, InterWell Health and Cricket Health, a premier value-based kidney care provider has been created in the U.S. This is an important step in the execution of Fresenius Medical Care's strategy. The new company operates under the InterWell Health brand and will be fully consolidated by Fresenius Medical Care as the majority owner. The closing of the merger resulted in a net gain of €56 million (on EBIT level) in the third quarter, which is treated as a special item.

<sup>1</sup> Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

<sup>2</sup> FY/21 base: €17,619 million

<sup>3</sup> FY/21 base: €1,018 million, before special items; FY/22 before special items

<sup>4</sup> These targets are based on the 2021 results excluding the costs related to FME25 of EUR 49 million (for Net Income). They are in constant currency and exclude special items. Special items include further costs related to FME25, the impact of the war in Ukraine, the impact of hyperinflation in Türkiye, the Humacyte investment remeasurement, the net gain related to InterWell Health and other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.

## FRESENIUS KABI

Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi is developing products with a focus on oncology and autoimmune diseases.

€ in millions	Q3/2022	Q3/2021	Growth	Growth in constant currency	Q1-3/2022	Q1-3/2021	Growth	Growth in constant currency
Sales	2,071	1,854	12%	4%	5,814	5,370	8%	2%
EBITDA <sup>1</sup>	397	414	-4%	-14%	1,172	1,194	-2%	-10%
EBIT <sup>1</sup>	280	300	-7%	-11% <sup>3</sup>	844	874	-3%	-9% <sup>3</sup>
Net income <sup>1,2</sup>	184	206	-11%	-21%	574	600	-4%	-13%
Employees (Sep. 30/Dec. 31)					42,257	41,397	2%	

- ▶ Solid organic sales growth in all three growth vectors against already strong Q3/21
- ▶ Biopharmaceuticals continue strong trajectory in line with ambitious plan
- ▶ Growth in Europe and rest of the world outweighing pressures in North America
- ▶ Sequentially constant EBIT margin<sup>3</sup> despite headwinds from cost increases

Sales increased by 12% (4% in constant currency) to €2,071 million (Q3/21: €1,854 million). Organic growth was 3%.

In Q1-3/22, sales increased by 8% (2% in constant currency) to €5,814 million (Q1-3/21: €5,370 million). Organic growth was 2%. Positive currency translation effects of 8% in Q3/22 and 6% in Q1-3/22 were mainly related to the U.S. dollar and Chinese yuan.

Sales in **North America** increased by 13% (organic growth: -2%) to €668 million (Q3/21: €589 million). The significant sales growth was mainly driven by positive currency effects while organic growth continued to be impacted by ongoing competitive pressure and supply chain challenges.

In Q1-3/22, sales in **North America** increased by 11% (organic growth: -1%) to €1,853 million (Q1-3/21: €1,669 million).

Sales in **Europe** increased by 8% (organic growth: 6%) to €669 million (Q3/21: €620 million) driven by a broad-based positive development, and biopharmaceuticals.

In Q1-3/22, sales in **Europe** increased by 5% (organic growth: 4%) to €1,967 million (Q1-3/21: €1,880 million).

Sales in **Asia-Pacific** increased by 4% (organic growth: -4%) to €467 million (Q3/21: €447 million). Organic growth was affected by price pressure from the NVBP (National Volume-Based Procurement) tenders in China.

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>3</sup> Excluding Ivenix and mAbxience acquisition



In Q1-3/22, sales in **Asia-Pacific** increased by 6% (organic growth: -2%) to €1,325 million (Q1-3/21: €1,248 million).

Sales in **Latin America/Africa** increased by 35% (organic growth: 27%) to €267 million (Q3/21: €198 million), due to a positive business development in both regions.

In Q1-3/22, sales in **Latin America/Africa** increased by 17% (organic growth: 11%) to €669 million (Q1-3/21: €573 million).

Sales in the **Biopharmaceuticals** business was €64 million.

In Q1-3/22, sales in the **Biopharmaceuticals** business was €116 million. **EBIT**<sup>1</sup> decreased by 7% (-18%/-11%<sup>2</sup> in constant currency) to €280 million (Q3/21: €300 million), mainly related to ongoing cost inflation, supply chain challenges as well as competitive pressure. EBIT margin<sup>1</sup> was 13.5% (Q3/21: 16.2%). Excluding the acquisitions of Ivenix and the majority stake in mAbxience, the constant currency EBIT margin<sup>1</sup> was sequentially stable at 14.6%<sup>2</sup> in Q3/22 (Q2/22: 14.7%<sup>2</sup>) despite the mentioned headwinds.

In Q1-3/22, **EBIT**<sup>1</sup> decreased by 3% (-12%/-9%<sup>2</sup> in constant currency) to €844 million (Q1-3/21: €874 million) with an EBIT margin<sup>1</sup> of 14.5%/15.0%<sup>2</sup> (Q1-3/21: 16.3%).

**Net income**<sup>1,3</sup> decreased by 11% (-21% in constant currency) to €184 million (Q3/21: €206 million).

In Q1-3/22, **net income**<sup>1,3</sup> decreased by 4% (-13% in constant currency) to €574 million (Q1-3/21: €600 million).

**Operating cash flow** decreased to €301 million (Q3/21: €393 million) with a margin of 14.5% (Q3/21: 21.2%), mainly driven by a working capital build-up from e.g. higher inventories.

In Q1-3/22, **operating cash flow** decreased to €543 million (Q1-3/21: €868 million) with a margin of 9.3% (Q1-3/21: 16.2%).

For FY/22, Fresenius Kabi confirms its outlook and expects organic sales<sup>4</sup> growth in a low-single-digit percentage range. Constant currency EBIT<sup>5</sup> is expected to decline in a high-single- to low-double-digit percentage range. Both sales and EBIT outlook include expected COVID-19 effects. The financial effects from the acquisitions of Ivenix and the majority stake in mAbxience remain excluded from guidance.

<sup>1</sup> Before special items

<sup>2</sup> Excluding Ivenix and mAbxience acquisition

<sup>3</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>4</sup> FY/21 base: €7,193 million

<sup>5</sup> FY/21 base: €1,153 million, before special items, FY/22 before special items, excluding Ivenix and mAbxience acquisitions

## FRESENIUS HELIOS

Fresenius Helios is Europe's leading private hospital operator. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 87 hospitals, ~130 outpatient centers and 6 prevention centers. Helios Spain operates 50 hospitals, 101 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.

€ in millions	Q3/2022	Q3/2021	Growth	Growth in constant currency	Q1-3/2022	Q1-3/2021	Growth	Growth in constant currency
Sales	2,829	2,622	8%	7%	8,685	8,009	8%	8%
EBITDA <sup>1</sup>	348	341	2%	1%	1,205	1,134	6%	6%
EBIT <sup>1</sup>	222	222	0%	-1%	831	788	5%	5%
Net income <sup>1,2</sup>	138	135	2%	1%	530	501	6%	5%
Employees (Sep. 30/Dec. 31)					125,977	123,484	2%	

- ▶ Fresenius Helios with strong organic sales growth; solid EBIT development in line with usual third quarter seasonality
- ▶ Helios Germany with gradually improving admissions
- ▶ Helios Spain with ongoing healthy activity levels
- ▶ Helios Fertility with lower volumes driven by delayed treatments

Sales increased by 8% (7% in constant currency) to €2,829 million (Q3/21: €2,622 million). Organic growth was 6%. Acquisitions, mainly at Helios Fertility, contributed 2% to sales growth. Divestments reduced sales by 1%.

In Q1-3/22, sales increased by 8% (8% in constant currency) to €8,685 million (Q1-3/21: €8,009 million). Organic growth was 6%. Acquisitions contributed 2% to sales growth.

Sales of **Helios Germany** increased by 6% (organic growth: 5%) to €1,731 million (Q3/21: €1,640 million), mainly driven by gradually increasing admissions, which are however still below pre-pandemic levels. Acquisitions contributed 1% to sales growth.

In Q1-3/22, sales of **Helios Germany** increased by 6% (organic growth: 5%) to €5,272 million (Q1-3/21: €4,988 million). Acquisitions contributed 1% to sales growth.

Sales of **Helios Spain** increased by 10% (9% in constant currency) to €1,037 million (Q3/21: €941 million). Organic growth of 8% was driven by the continuous high level of treatment activity. The clinics in Latin America also showed a good performance. Acquisitions contributed 1% to sales growth.

In Q1-3/22, sales of **Helios Spain** increased by 10% (9% in constant currency) to €3,227 million (Q1-3/21: €2,937 million). Organic growth was 9%.

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

Sales of the **Helios Fertility** were €62 million (Q3/21: €40 million).

In Q1-3/22, sales of the **Helios Fertility** were €184 million.

**EBIT<sup>1</sup>** remained stable (-1% in constant currency) at €222 million (Q3/21: €222 million) with an EBIT margin<sup>1</sup> of 7.8% (Q3/21: 8.5%).

In Q1-3/22, **EBIT<sup>1</sup>** increased by 5% (5% in constant currency) to €831 million (Q1-3/21: 788 million) with an EBIT margin<sup>1</sup> of 9.6% (Q1-3/21: 9.8%).

**EBIT<sup>1</sup>** of **Helios Germany** increased by 1% to €141 million (Q3/21: €140 million) with an EBIT margin<sup>1</sup> of 8.1% (Q3/21: 8.5%). The increase of costs from the use of external staff due to COVID-19 related staff absenteeism continued to weigh on profitability. Inflationary cost effects had only a small negative impact.

In Q1-3/22, **EBIT<sup>1</sup>** of **Helios Germany** increased by 2% to €449 million (Q1-3/21: €442 million) with an EBIT margin<sup>1</sup> of 8.5% (Q1-3/21: 8.9%).

**EBIT<sup>1</sup>** of **Helios Spain** increased by 5% (3% in constant currency) to €83 million (Q3/21: €79 million) despite increased cost inflation. The EBIT margin<sup>1</sup> was 8.0% (Q3/21: 8.4%).

In Q1-3/22, **EBIT<sup>1</sup>** of **Helios Spain** increased by 9% (9% in constant currency) to €384 million (Q1-3/21: €352 million). The EBIT margin<sup>1</sup> was 11.9% (Q1-3/21: 12.0%).

**EBIT<sup>1</sup>** of **Helios Fertility** was €4 million with an EBIT margin<sup>1</sup> of 6.5% (Q3/21: €9 million). Lower volumes by delayed treatments driven by macroeconomic environment. Prior year quarter was inflated by a positive special item.

In Q1-3/22, **EBIT<sup>1</sup>** of **Helios Fertility** was €15 million (Q1-3/21: €14 million) with an EBIT margin<sup>1</sup> of 8.2%.

**Net income<sup>1,2</sup>** increased by 2% (1% in constant currency) to €138 million (Q3/21: €135 million).

In Q1-3/22, **net income<sup>1,2</sup>** increased by 6% (5% in constant currency) to €530 million (Q1-3/21: €501 million).

**Operating cash flow** increased to €353 million (Q3/21: €157 million) with a margin of 12.5% (Q3/21: 6.0%) mainly due to an improved receivables management in Spain.

In Q1-3/22, **operating cash flow** decreased to €411 million (Q1-3/21: €595 million) with a margin of 4.7% (Q1-3/21: 7.4%).

For FY/22, Fresenius Helios confirms its outlook and expects organic sales<sup>3</sup> growth in a low- to mid-single-digit percentage range and constant currency EBIT<sup>4</sup> growth in a mid-single-digit percentage range. Both sales and EBIT outlook include expected COVID-19 effects.

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>3</sup> FY/21 base: €10,891 million

<sup>4</sup> FY/21 base: €1,127 million, before special items, FY/22 before special items

## FRESENIUS VAMED

**Fresenius Vamed manages projects and provides services for hospitals and other healthcare facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.**

€ in millions	Q3/2022	Q3/2021	Growth	Growth in constant currency	Q1-3/2022	Q1-3/2021	Growth	Growth in constant currency
Sales	572	516	11%	10%	1,647	1,549	6%	6%
EBITDA <sup>1</sup>	35	45	-22%	-24%	102	100	2%	0%
EBIT <sup>1</sup>	10	23	-57%	-61%	29	35	-17%	-20%
Net income <sup>1,2</sup>	5	14	-64%	-64%	15	18	-17%	-17%
Employees (Sep 30/Dec. 31)					20,017	19,721	2%	

- ▶ **Service business with solid top-line performance, but higher than estimated COVID-19 impact in rehabilitation business impacts earnings**
- ▶ **Despite improved top-line development, macro challenges remain a headwind in the project business**
- ▶ **Revaluation of contractual assets in the international service and project business weighed on EBIT development**

**Sales** increased by 11% (10% in constant currency) to €572 million (Q3/21: €516 million). Organic growth was 10%.

In Q1-3/22, **sales** increased by 6% (6% in constant currency) to €1,647 million (Q1-3/21: €1,549 million). Organic growth was 6%.

Sales in the **service business** increased by 2% (1% in constant currency) to €418 million (Q3/21: €410 million) due to increasing rehabilitation treatments given fewer capacity restrictions.

Sales in the **project business** increased by 45% (45% in constant currency) to €154 million (Q3/21: €106 million).

In Q1-3/22, sales in the **service business** increased by 6% (5% in constant currency) to €1,240 million (Q1-3/21: €1,165 million).

Sales in the **project business** increased by 6% (6% in constant currency) to €407 million (Q1-3/21: €384 million).

**EBIT<sup>1</sup>** decreased by 57% to €10 million (Q3/21: €23 million) with an EBIT margin<sup>1</sup> of 1.7% (Q3/21: 4.5%)

driven by macroeconomic headwinds, ongoing COVID impacts, cost inflation as well as the revaluation of contractual assets in the international service and project business.

In Q1-3/22, **EBIT<sup>1</sup>** decreased by 17% to €29 million (Q1-3/21: €35 million) with an EBIT margin<sup>1</sup> of 1.8% (Q1-3/21: 2.3%).

**Net income<sup>1,2</sup>** decreased by 64% to €5 million (Q3/21: €14 million).

In Q1-3/22, **Net income<sup>1,2</sup>** decreased by 17% to €15 million (Q1-3/21: €18 million).

<sup>1</sup> Before special items

<sup>2</sup> Net income attributable to shareholders of VAMED AG

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

**Order intake** was €153 million (Q3/21: €120 million). In Q1-3/22 **order intake** was €669 million (Q1-3/21: €971 million). As of September 30, 2022, **order backlog** was at €3,726 million (December 31, 2021: €3,473 million).

**Operating cash flow** decreased to -€18 million (Q3/21: €9 million) with a margin of -3.1% (Q3/21: 1.7%), due to working capital build-ups.

In Q1-3/22, **operating cash flow** decreased to -€56 million (Q1-3/21: €23 million) with a margin of -3.4% (Q1-3/21: 1.5%).

Fresenius Vamed adjusts its outlook for FY/22 and now expects organic sales<sup>1</sup> to grow in a mid-single digit percentage range (previously: high-single to low-double-digit percentage range). Constant currency EBIT<sup>2</sup> is expected to be around €100 million (previously: return to absolute pre-COVID-19 levels (FY/19: €134 million)). Both sales and EBIT outlook include expected COVID-19 effects.

<sup>1</sup> FY/21 base: €2,297 million

<sup>2</sup> FY/21 base: €101 million, before special items; FY/22 before special items

For a detailed overview of special items please see the reconciliation tables on page 28 onwards.

## EMPLOYEES

As of September 30, 2022, the number of employees was 319,691 (Dec. 31, 2021: 316,078).

### NUMBER OF EMPLOYEES

Number of employees	Sep. 30, 2022	Dec. 31, 2021	Growth
Fresenius Medical Care	130,295	130,251	0%
Fresenius Kabi	42,257	41,397	2%
Fresenius Helios	125,977	123,484	2%
Fresenius Vamed	20,017	19,721	2%
Corporate	1,145	1,225	-7%
<b>Total</b>	<b>319,691</b>	<b>316,078</b>	<b>1%</b>

## CHANGES TO THE SUPERVISORY BOARD

The Annual General Meeting of Fresenius SE & Co. KGaA elected Dr. Christoph Zindel (60), member of the Management Board of Siemens Healthineers since October 2019, to the Supervisory Board of Fresenius SE & Co. KGaA. Dr. Christoph Zindel is a member of the Audit Committee of the Supervisory Board.

As announced a year ago, Klaus-Peter Müller (77) stepped down from the Supervisory Board at the end of the Annual General Meeting and handed over the chairmanship of its Audit Committee to Susanne Zeidler (61).

## CHANGES TO THE MANAGEMENT BOARD

Michael Sen (53) is Chief Executive Officer of Fresenius since October 1, 2022. He was appointed unanimously by the Supervisory Board of Fresenius Management SE to succeed Stephan Sturm (59), who left the company on good terms on September 30, 2022. Michael Sen will, in addition, continue to serve as CEO of Fresenius Kabi until a successor is decided for this position.

The Fresenius Management SE Supervisory Board has unanimously appointed Sara Hennicken (41) to the company's new Chief Financial Officer as of September 1, 2022. She succeeds Rachel Empey (45), who joined the Management Board of Fresenius as CFO on August 1, 2017 and left the company at her own request at the end of August.

Dr. Carla Kriwet (51) is the new CEO of Fresenius Medical Care. The Supervisory Board of Fresenius Medical Care Management AG unanimously appointed her to succeed Rice Powell (66), who in accordance with the company's age limit for Management Board members was stepping down after 10 years heading the company. Like Rice Powell, Dr. Carla Kriwet is also a member of the Management Board of Fresenius Management SE. Dr. Carla Kriwet joined Fresenius Medical Care as CEO on October 1, 2022, earlier than previously announced and Rice Powell stepped down as CEO effective September 30, 2022.

Additionally, Helen Giza, Chief Financial Officer of Fresenius Medical Care has entered a new five-year contract and, in addition to her current positions as Chief Financial Officer and Chief Transformation Officer of Fresenius Medical Care Management AG, has assumed the position of Deputy Chief Executive Officer of Fresenius Medical Care Management AG.

The CVs of the members of the Supervisory Board and the Management Board can be found on our website at <https://www.fresenius.com/Corporate-Management>.

## RESEARCH AND DEVELOPMENT

Product and process development as well as the improvement of therapies are at the core of our growth strategy. Fresenius focuses its R & D efforts on its core competencies in the following areas:

- ▶ Dialysis
- ▶ Generic IV drugs
- ▶ Biosimilars
- ▶ Infusion and nutrition therapies
- ▶ Medical devices

Apart from new products, we are concentrating on developing optimized or completely new therapies, treatment methods, and services.

### RESEARCH AND DEVELOPMENT EXPENSES BY BUSINESS SEGMENT

€ in millions	Q1- 3/2022	Q1- 3/2021	Growth
Fresenius Medical Care	166 <sup>1</sup>	153	8%
Fresenius Kabi	422 <sup>1</sup>	443	-5%
Fresenius Helios	2	2	0%
Fresenius Vamed	-	-	--
Corporate	-2	0	--
<b>Total</b>	<b>588<sup>1</sup></b>	<b>598</b>	<b>-2%</b>

<sup>1</sup> Before special items

## RATING

Fresenius is covered by the rating agencies Moody's, Standard & Poor's and Fitch.

The following table shows the company rating of Fresenius SE & Co. KGaA:

	Standard & Poor's	Moody's	Fitch
Company rating	BBB	Baa3	BBB -
Outlook	stable	stable	stable

## OPPORTUNITIES AND RISK REPORT

Compared to the presentation in the consolidated financial statements and the management report as of December 31, 2021 applying Section 315e HGB in accordance with IFRS, there has been the following important developments in Fresenius' overall opportunities and risk situation until September 30, 2022.

Russia's war against the Ukraine, will continue to have a significant negative impact on our net assets, financial position, and results of operations. As a provider of life-sustaining medical products and healthcare services, we are continuing our activities in both, Russia, and Ukraine to the best of our ability despite the war and the restrictions resulting from the extensive economic sanctions imposed on Russia and Belarus by numerous governments. However, we cannot exclude that operations in Ukraine, Russia and Belarus are impacted by the destruction of assets, expropriation, or other regulatory actions.

In addition to such risks, considerable uncertainties are related to a further deterioration of the global macroeconomic outlook. While the direct and indirect impact of the war is difficult to predict at the present time, the current, significant macroeconomic inflationary environment, including materially increasing energy prices, has resulted in and could continue to lead to, amongst other consequences, material increases in costs for energy, supplies, and transportation.

Furthermore, supply chain disruptions as well as qualified labor shortages and related increases in labor costs

present risks which adversely effect our business operations. In order to limit these cost increases for Fresenius, we continuously analyze and use potential savings, for example in energy consumption. Thus, we examine the use of alternative energy sources in order to deploy them wherever possible.

The discontinuation of energy supplies from Russia increases these impacts and has additional material adverse effects on our business. An expansion of the war beyond the borders of Ukraine would bring further significant consequences for Europe as a whole.

Additionally, the Ukraine War has increased the risk of cyber security attacks against our systems and data.

Furthermore, our ability to access capital could be impacted by increased volatility and disruptions in the financing markets, and further rises in interest rates.

Overall, the abovementioned factors will have a negative impact on our net assets, financial position, and results of operations.

The global COVID-19 pandemic also continued to adversely affect our business in the first nine months of 2022. The further development of the worldwide situation in 2022 remains uncertain and depends on the extent to which further virus variants spread and on the governmental responses in the regions we operate in or source from. An unfavourable development may result in additional adverse effects on our financial results and our ability to achieve our Guidance.

In the ordinary course of Fresenius Group's operations, the Fresenius Group is subject to litigation, arbitration as well as external and internal investigations relating to various aspects of its business. The Fresenius Group regularly

analyses current information about such matters for probable losses and provides accruals for such matters, including estimated expenses for legal services, as appropriate. We report on legal proceedings on pages 60 to 61 in the Notes of this report.

## SUBSEQUENT EVENTS

October 2022 was characterized worldwide by a regionally varying development of the COVID-19 pandemic with continuing high infection numbers and associated shortage of resources. The further development of the global situation and its impact on Fresenius remain uncertain.

Russia's ongoing war against Ukraine and the associated price increases, especially for energy, raw materials and transport, will continue to have a direct and indirect negative impact on the business activities of the Fresenius Group, which cannot be estimated at present.

The development of personnel costs and the disruption of supply chains also remain issues on a global level. Their impact on Fresenius will be continuously analyzed in detail.

Beyond that, there have been no significant changes in the industry environment since the end of the third quarter.

Also otherwise, there have been no further events with a significant impact on the net assets, financial position, and results of operations since the end of the third quarter of 2022.



## OUTLOOK 2022

### ASSUMPTIONS FOR GUIDANCE FY/22

For 2022 and beyond, Fresenius expects that the current challenging market environment and the global macro-economic headwinds will remain. In particular, the general cost inflation, labor shortages, meaningful uncertainty with regard to the future development of energy prices, burdens from supply chain disruptions and ongoing impacts of the COVID-19 pandemic are expected to continue. The guidance does not consider a significant disruption of gas or electricity supplies in Europe.

Fresenius will continue to closely monitor the potential further consequences of the overall heightened volatility and muted visibility, including balance sheet valuations.

The war in Ukraine is directly and indirectly affecting Fresenius Group operations. The direct adverse effects of the war amounted to €24 million at net income<sup>1</sup> level of Fresenius Group in Q1-3/22 and are treated as a special item.

COVID-19 will continue to impact Fresenius Group operations in 2022. An unlikely but possible significant deterioration of the situation triggering containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation is not reflected in the Group's FY/22 guidance.

For Fresenius Medical Care's contribution to the Group's financial figures, the assumptions for Fresenius Medical Care's FY/22 guidance are also fully applicable to Fresenius Group's FY/22 guidance.

All of these assumptions are subject to considerable uncertainty.

The acquisitions of Ivenix and of the majority stake in mAbxience as well as any further potential acquisitions remain excluded from guidance.

### FRESENIUS GROUP

Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company's focused efforts to improve North American Health Care Services operations are delayed against previous assumptions. Therefore, Fresenius Medical Care now assumes lower contributions in the financial year 2022.

Consequently, Fresenius Medical Care now expects net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) for the financial year 2022 to decline in the high teens to mid-twenties percentage range. The Company continues to anticipate revenue to grow at a low-single digit percentage range in the financial year 2022. These targets are in constant currency and exclude special items.

All other business segments of the Fresenius Group, in particular Vamed, are also affected by a challenging overall economic environment. Thus, there are increased uncertainties, inflation-related cost increases, staff shortages, disruptions in supply chains, and increased energy costs. This has a direct impact on customer and patient behavior.

However, as a consequence of the development at Fresenius Medical Care, Fresenius Vamed, and in view of increasing indications of a persistent unfavorable development of these and other factors for the further course of the financial year, the Management Board has changed its risk assessment and consequently also adjusted the Group outlook for FY/22.

At constant currency, the Company now anticipates Group net income<sup>1,2</sup> to decline around ten percent (previously: decline in a low-to-mid single-digit percentage range). Group sales<sup>3</sup> in constant currency continue to be expected to grow in a low-to-mid single-digit percentage range.

### SALES AND EARNINGS BY BUSINESS SEGMENT

In 2022, we expect sales and earnings development in our business segments as shown in the table on page 27.

### COST AND EFFICIENCY PROGRAM

The Group's cost and efficiency program is running according to plan and Fresenius confirms its increased savings targets provided in February 2022 of at least €150 million p.a. after tax and minority interest in 2023. For the years thereafter, a further significant increase in sustainable cost savings is expected.

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>2</sup> FY/21 base: €1,867 million; before special items; FY/22: before special items

<sup>3</sup> FY/21 base: €37,520 million

## EXPENSES

For 2022, we do not expect selling, general, and administrative expenses (before special items) as a percentage of consolidated net sales to change significantly compared to 2021 (2021: 14.1%).

## LIQUIDITY AND CAPITAL MANAGEMENT

For 2022, we now expect an operating cash flow margin in the range of 8% to 10% (previously: in the range of 10% to 12%).

In addition, undrawn credit lines under syndicated or bilateral credit facilities from banks provide us with a sufficient financial headroom.

Financing activities in 2022 are largely geared to refinancing existing financial liabilities maturing in 2022 and 2023.

Without the closed acquisition of Ivenix and the completed acquisition of a majority stake in mAbxience as well as any further potential acquisitions, Fresenius expects the net debt/EBITDA<sup>1</sup> ratio to be roughly on the same level as in Q3/22 (3.64x<sup>2</sup>) by the end of 2022 (December 31, 2021: 3.51x<sup>2</sup>). There are no significant changes in the financing strategy planned for 2022.

## INVESTMENTS

In 2022, we now expect to invest about 5% (previously: about 6%) of sales in property, plant and equipment. About 45% of the capital expenditure planned will be invested at Fresenius Medical Care, about 23% at Fresenius Kabi, and around 27% at Fresenius Helios.

At Fresenius Medical Care, investments will primarily be used for the expansion of production capacity, optimizing production costs, and the establishment of new dialysis clinics.

Fresenius Kabi will primarily invest in expanding and maintaining production facilities, as well as in introducing new manufacturing technologies.

At Fresenius Helios, we will primarily invest in the new buildings, and in the modernizing and equipping of existing hospitals, newly acquired hospitals, and outpatient centers.

Fresenius Vamed primarily invests in modernization as well as equipment for existing post-acute care facilities.

With a share of around 60%, Europe is the regional focus of investment in the planning period. Around 30% of the investments are planned for North America and around 10% for Asia-Pacific, Latin America, and Africa. About 30% of total funds will be invested in Germany.

For 2022, we expect return on operating assets (ROOA) to decline by 80 to 100 basis points (previously: 50 to 80 basis points) compared with the prior-year figure (2021: 6.5%). Return on invested capital (ROIC) is expected to decline by 80 to 100 basis points (previously: 40 to 70 basis points; 2021: 5.9%).

## CAPITAL STRUCTURE

For 2022, we do not expect the equity ratio to change significantly compared to 2021 (2021: 41%). Furthermore, we expect debt in relation to total assets to remain around the prior year's level (2021: 38%).

## DIVIDEND

The dividend increases provided by Fresenius in the last 29 years show impressive continuity. Our dividend policy aims to align dividends with earnings-per-share growth (before special items). The payout ratio is expected to be in the range of approximately 20% to 25%. For 2022, our dividend will be based upon our final results, but we aim to keep our dividend at least constant.

<sup>1</sup> At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; excluding further potential acquisitions; before special items; including lease liabilities

<sup>2</sup> At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; including lease liabilities

GROUP FINANCIAL OUTLOOK 2022

	Fiscal year 2021 <sup>1</sup>	Targets 2022 <sup>2</sup> (February 2022)	Targets 2022 <sup>2</sup> (adjusted July 2022)	Guidance <sup>2</sup>
Sales growth (in constant currency)	€37,520 m	Mid single-digit percentage growth	Growth in a low-to-mid single-digit percentage range	confirmed
Net income <sup>3</sup> growth (in constant currency)	€1,867 m	Low single-digit percentage growth	Decline in a low-to-mid single-digit percentage range	Decline around ten percent

<sup>1</sup> Before special items, including COVID-19 effects

<sup>2</sup> Before special items, including estimated COVID-19 effects

<sup>3</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

OUTLOOK 2022 BY BUSINESS SEGMENT

	Fiscal year 2021 <sup>1</sup>	Targets 2022 <sup>2</sup> (February 2022)	Targets 2022 <sup>2</sup> (adjusted July 2022)	Guidance <sup>2</sup>
<b>Fresenius Medical Care<sup>3</sup></b>				
Sales growth (in constant currency)	€17,619 m	Low-to-mid single-digit percentage growth	Low single-digit percentage growth	confirmed
Net income <sup>4</sup> growth (in constant currency)	€1,018 m	Low-to-mid single-digit percentage growth	Decline at around a high teens percentage range	Decline in the high teens to mid-twenties percentage range
<b>Fresenius Kabi</b>				
Sales growth (organic)	€7,193 m	Low single-digit percentage growth	confirmed	confirmed
EBIT growth (in constant currency)	€1,153 m	Decline in high single- to low double-digit percentage range	confirmed	confirmed
<b>Fresenius Helios</b>				
Sales growth (organic)	€10,891 m	Low-to-mid single-digit percentage growth	confirmed	confirmed
EBIT growth (in constant currency)	€1,127 m	Mid single-digit percentage growth	confirmed	confirmed
<b>Fresenius Vamed</b>				
Sales growth (organic)	€2,297 m	High single- to low double-digit percentage growth	confirmed	Growth in a mid-single digit percentage range
EBIT	€101 m	Returning to absolute pre-COVID levels (2019: €134 m)	confirmed	Around €100 million

<sup>1</sup> Before special items, including COVID-19 effects

<sup>2</sup> Before special items, including estimated COVID-19 effects

<sup>3</sup> These targets are based on the 2021 results excluding the costs related to FME25 of EUR 49 million (for Net Income). They are in constant currency and exclude special items. Special items include further costs related to FME25, the impact of the war in Ukraine, the impact of hyperinflation in Türkiye, the Humacyte investment remeasurement, the net gain related to InterWell Health and other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.

<sup>4</sup> Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

## RECONCILIATION TABLES

### RECONCILIATION FRESENIUS GROUP Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Sales reported</b>	<b>10,459</b>	<b>9,324</b>	<b>12%</b>	<b>5%</b>	<b>30,197</b>	<b>27,554</b>	<b>10%</b>	<b>4%</b>
<b>EBIT reported (after special items)</b>	<b>887</b>	<b>1,008</b>	<b>-12%</b>	<b>-21%</b>	<b>2,634</b>	<b>3,035</b>	<b>-13%</b>	<b>-19%</b>
Revaluations of biosimilars contingent purchase price liabilities	-	-			-2	-		
Expenses associated with the Fresenius cost and efficiency program	97	36			211	51		
Impacts related to the war in Ukraine	4	-			44	-		
Transaction costs mAbxience, Ivenix	15	-			22	-		
Hyperinflation Turkey	1	-			11	-		
Retroactive duties	-	-			9	-		
Remeasurement Humacyte investment	1	-			79	-		
Net Gain related to InterWell Health	-56	-			-56	-		
<b>EBIT (before special items)</b>	<b>949</b>	<b>1,044</b>	<b>-9%</b>	<b>-17%</b>	<b>2,952</b>	<b>3,086</b>	<b>-4%</b>	<b>-10%</b>
<b>Net interest reported (after special items)</b>	<b>-141</b>	<b>-126</b>	<b>-12%</b>	<b>-4%</b>	<b>-375</b>	<b>-384</b>	<b>2%</b>	<b>8%</b>
Revaluations of biosimilars contingent purchase price liabilities	-	-			-1	-		
<b>Net interest (before special items)</b>	<b>-141</b>	<b>-126</b>	<b>-12%</b>	<b>-4%</b>	<b>-376</b>	<b>-384</b>	<b>2%</b>	<b>8%</b>
<b>Income taxes reported (after special items)</b>	<b>-195</b>	<b>-201</b>	<b>3%</b>	<b>13%</b>	<b>-545</b>	<b>-591</b>	<b>8%</b>	<b>14%</b>
Revaluations of biosimilars contingent purchase price liabilities	-	-			1	-		
Expenses associated with the Fresenius cost and efficiency program	-23	-9			-49	-14		
Impacts related to the war in Ukraine	0	-			-4	-		
Transaction costs mAbxience, Ivenix	-2	-			-3	-		
Hyperinflation Turkey	0	-			0	-		
Retroactive duties	-	-			-3	-		
Remeasurement Humacyte investment	0	-			-21	-		
Net Gain related to InterWell Health	18	-			18	-		
<b>Income taxes (before special items)</b>	<b>-202</b>	<b>-210</b>	<b>4%</b>	<b>12%</b>	<b>-606</b>	<b>-605</b>	<b>0%</b>	<b>6%</b>

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Noncontrolling interests reported (after special items)</b>	<b>-230</b>	<b>-268</b>	<b>14%</b>	<b>23%</b>	<b>-597</b>	<b>-741</b>	<b>19%</b>	<b>26%</b>
Expenses associated with the Fresenius cost and efficiency program	-27	-5			-53	-10		
Impacts related to the war in Ukraine	0	-			-16	-		
Transaction costs mAbxience, Ivenix	-2	-			-2	-		
Hyperinflation Turkey	0	-			-4	-		
Remeasurement Humacyte investment	-2	-			-40	-		
Net Gain related to InterWell Health	26	-			26	-		
<b>Noncontrolling interests (before special items)</b>	<b>-235</b>	<b>-273</b>	<b>14%</b>	<b>23%</b>	<b>-686</b>	<b>-751</b>	<b>9%</b>	<b>16%</b>
<b>Net income reported (after special items)<sup>1</sup></b>	<b>321</b>	<b>413</b>	<b>-22%</b>	<b>-30%</b>	<b>1,117</b>	<b>1,319</b>	<b>-15%</b>	<b>-20%</b>
Revaluations of biosimilars contingent purchase price liabilities	-	-			-2	-		
Expenses associated with the Fresenius cost and efficiency program	47	22			109	27		
Impacts related to the war in Ukraine	4	-			24	-		
Transaction costs mAbxience, Ivenix	11	-			17	-		
Hyperinflation Turkey	1	-			7	-		
Retroactive duties	-	-			6	-		
Remeasurement Humacyte investment	-1	-			18	-		
Net Gain related to InterWell Health	-12	-			-12	-		
<b>Net income (before special items)<sup>1</sup></b>	<b>371</b>	<b>435</b>	<b>-15%</b>	<b>-22%</b>	<b>1,284</b>	<b>1,346</b>	<b>-5%</b>	<b>-10%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

## RECONCILIATION FRESENIUS MEDICAL CARE Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Sales reported</b>	<b>5,096</b>	<b>4,441</b>	<b>15%</b>	<b>3%</b>	<b>14,401</b>	<b>12,972</b>	<b>11%</b>	<b>2%</b>
<b>EBIT reported (after special items)</b>	<b>472</b>	<b>505</b>	<b>-7%</b>	<b>-17%</b>	<b>1,160</b>	<b>1,403</b>	<b>-17%</b>	<b>-24%</b>
Costs related to FME25 program	53	8			109	20		
Impacts related to the war in Ukraine	0	-			24	-		
Hyperinflation Turkey	0	-			6	-		
Remeasurement Humacyte investment	1	-			79	-		
Net Gain related to InterWell Health	-56	-			-56	-		
<b>EBIT (before special items)</b>	<b>470</b>	<b>513</b>	<b>-8%</b>	<b>-18%</b>	<b>1,322</b>	<b>1,423</b>	<b>-7%</b>	<b>-14%</b>
<b>Net income reported (after special items)<sup>1</sup></b>	<b>230</b>	<b>273</b>	<b>-16%</b>	<b>-24%</b>	<b>535</b>	<b>741</b>	<b>-28%</b>	<b>-34%</b>
Costs related to FME25 program	38	7			78	15		
Impacts related to the war in Ukraine	0	-			21	-		
Hyperinflation Turkey	0	-			6	-		
Remeasurement Humacyte investment	1	-			58	-		
Net Gain related to InterWell Health	-38	-			-38	-		
<b>Net income (before special items)<sup>1</sup></b>	<b>231</b>	<b>280</b>	<b>-17%</b>	<b>-25%</b>	<b>660</b>	<b>756</b>	<b>-13%</b>	<b>-18%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

## RECONCILIATION FRESENIUS KABI Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Sales reported</b>	<b>2,071</b>	<b>1,854</b>	<b>12%</b>	<b>4%</b>	<b>5,814</b>	<b>5,370</b>	<b>8%</b>	<b>2%</b>
Revaluations of biosimilars contingent purchase price liabilities	-	-			-2	-		
Expenses associated with the Fresenius cost and efficiency program	31	26			77	26		
Impacts related to the war in Ukraine	2	-			14	-		
Transaction costs mAbxience, Ivenix	15	-			22	-		
Hyperinflation Turkey	1	-			5	-		
<b>EBIT (before special items)</b>	<b>280</b>	<b>300</b>	<b>-7%</b>	<b>-18%</b>	<b>844</b>	<b>874</b>	<b>-3%</b>	<b>-12%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

<sup>1</sup> Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

## RECONCILIATION FRESENIUS HELIOS Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Sales reported</b>	<b>2,829</b>	<b>2,622</b>	<b>8%</b>	<b>7%</b>	<b>8,685</b>	<b>8,009</b>	<b>8%</b>	<b>8%</b>
Expenses associated with the Fresenius cost and efficiency program	0	1			0	1		
<b>EBIT (before special items)</b>	<b>222</b>	<b>222</b>	<b>0%</b>	<b>-1%</b>	<b>831</b>	<b>788</b>	<b>5%</b>	<b>5%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

## RECONCILIATION FRESENIUS VAMED Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
<b>Sales reported</b>	<b>572</b>	<b>516</b>	<b>11%</b>	<b>10%</b>	<b>1,647</b>	<b>1,549</b>	<b>6%</b>	<b>6%</b>
Expenses associated with the Fresenius cost and efficiency program	0	-			2	-		
Impacts related to the war in Ukraine	1	-			6	-		
<b>EBIT (before special items)</b>	<b>10</b>	<b>23</b>	<b>-57%</b>	<b>-61%</b>	<b>29</b>	<b>35</b>	<b>-17%</b>	<b>-20%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

## RECONCILIATION FRESENIUS CORPORATE Q3 AND Q1-3

€ in millions	Q3/2022	Q3/2021	Growth rate	Growth rate in constant currency	Q1-3/2022	Q1-3/2021	Growth rate	Growth rate in constant currency
Expenses associated with the Fresenius cost and efficiency program	14	1			23	4		
Retroactive duties	-	-			9	-		
<b>EBIT (before special items)</b>	<b>-33</b>	<b>-14</b>	<b>-136%</b>	<b>-121%</b>	<b>-74</b>	<b>-34</b>	<b>-118%</b>	<b>-115%</b>

The special items shown within the reconciliation tables are reported in the Corporate segment.

## ESTIMATED COVID-19 EFFECTS Q3 AND Q1-3

€ in millions	Reported growth rate in constant currency including COVID-19-effects		Estimated COVID-19 impact in constant currency		Estimated growth rate in constant currency excluding COVID-19-effects	
	Q3/2022	Q3/2021	Q3/2022	Q3/2021	Q3/2022	Q3/2021
Sales	5%	5%	1 to 0%	-2 to -3%	4 to 5%	7 to 8%
Net income (before special items) <sup>1</sup>	-22%	2%	4 to 0%	-10 to -14%	-26 to -22%	12 to 16%

€ in millions	Reported growth rate in constant currency including COVID-19-effects		Estimated COVID-19 impact in constant currency		Estimated growth rate in constant currency excluding COVID-19-effects	
	Q1-3/2022	Q1-3/2021	Q1-3/2022	Q1-3/2021	Q1-3/2022	Q1-3/2021
Sales	4%	5%	1 to 0%	0 to -1%	3 to 4%	5 to 6%
Net income (before special items) <sup>1</sup>	-10%	6%	5 to 1%	-1 to -5%	-15 to -11%	7 to 11%

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA



## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)

€ in millions

	Q3/2022	Q3/2021	Q1-3/2022	Q1-3/2021
Sales	10,459	9,324	30,197	27,554
Cost of sales	-7,754	-6,801	-22,256	-19,955
<b>Gross profit</b>	<b>2,705</b>	<b>2,523</b>	<b>7,941</b>	<b>7,599</b>
Selling, general and administrative expenses	-1,609	-1,300	-4,717	-3,966
Research and development expenses	-209	-215	-590	-598
<b>Operating income (EBIT)</b>	<b>887</b>	<b>1,008</b>	<b>2,634</b>	<b>3,035</b>
Net interest	-141	-126	-375	-384
<b>Income before income taxes</b>	<b>746</b>	<b>882</b>	<b>2,259</b>	<b>2,651</b>
Income taxes	-195	-201	-545	-591
<b>Net income</b>	<b>551</b>	<b>681</b>	<b>1,714</b>	<b>2,060</b>
Noncontrolling interests	230	268	597	741
<b>Net income attributable to shareholders of Fresenius SE &amp; Co. KGaA</b>	<b>321</b>	<b>413</b>	<b>1,117</b>	<b>1,319</b>
<b>Earnings per share in €</b>	<b>0.57</b>	<b>0.74</b>	<b>1.99</b>	<b>2.36</b>
Fully diluted earnings per share in €	0.57	0.74	1.99	2.36

The following notes are an integral part of the unaudited condensed interim financial statements.

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)

€ in millions

	Q3/2022	Q3/2021	Q1 – 3/2022	Q1 – 3/2021
<b>Net income</b>	<b>551</b>	<b>681</b>	<b>1,714</b>	<b>2,060</b>
<b>Other comprehensive income (loss)</b>				
<b>Positions which will be reclassified into net income in subsequent years</b>				
Foreign currency translation	1,529	421	3,403	1,031
Cash flow hedges	2	5	3	-2
FVOCI debt instruments	-14	-2	-47	-9
Income taxes on positions which will be reclassified	6	-	17	5
<b>Positions which will not be reclassified into net income in subsequent years</b>				
Actuarial gains (losses) on defined benefit pension plans	105	-3	627	84
Equity method investees - share of OCI	38	4	27	-46
FVOCI equity investments	9	-37	15	-12
Income taxes on positions which will not be reclassified	-32	14	-188	-20
<b>Other comprehensive income, net</b>	<b>1,643</b>	<b>402</b>	<b>3,857</b>	<b>1,031</b>
<b>Total comprehensive income</b>	<b>2,194</b>	<b>1,083</b>	<b>5,571</b>	<b>3,091</b>
<b>Comprehensive income attributable to noncontrolling interests</b>	<b>970</b>	<b>496</b>	<b>2,342</b>	<b>1,270</b>
<b>Comprehensive income attributable to shareholders of Fresenius SE &amp; Co. KGaA</b>	<b>1,224</b>	<b>587</b>	<b>3,229</b>	<b>1,821</b>

The following notes are an integral part of the unaudited condensed interim financial statements.

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

#### ASSETS

€ in millions	September 30, 2022	December 31, 2021
Cash and cash equivalents	2,128	2,764
Trade accounts and other receivables, less allowances for expected credit losses	7,977	7,045
Accounts receivable from and loans to related parties	169	147
Inventories	4,999	4,218
Other current assets	4,170	3,287
<b>I. Total current assets</b>	<b>19,443</b>	<b>17,461</b>
Property, plant and equipment	13,251	12,569
Right-of-use assets	6,376	6,014
Goodwill	33,265	28,943
Other intangible assets	4,584	3,831
Other non-current assets	2,328	2,286
Deferred taxes	1,081	858
<b>II. Total non-current assets</b>	<b>60,885</b>	<b>54,501</b>
<b>Total assets</b>	<b>80,328</b>	<b>71,962</b>

#### LIABILITIES

€ in millions	September 30, 2022	December 31, 2021
Trade accounts payable	1,926	2,039
Short-term accounts payable to related parties	71	92
Short-term provisions and other short-term liabilities	9,121	7,915
Short-term debt	1,608	2,841
Short-term debt from related parties	11	8
Current portion of long-term debt	528	473
Current portion of lease liabilities	911	832
Current portion of bonds	308	618
Short-term liabilities for income taxes	378	244
<b>A. Total short-term liabilities</b>	<b>14,862</b>	<b>15,062</b>
Long-term debt, less current portion	2,343	2,127
Lease liabilities, less current portion	6,130	5,758
Bonds, less current portion	16,280	14,016
Convertible bonds	488	482
Long-term provisions and other long-term liabilities	2,792	1,788
Pension liabilities	1,124	1,675
Long-term liabilities for income taxes	269	251
Deferred taxes	1,884	1,515
<b>B. Total long-term liabilities</b>	<b>31,310</b>	<b>27,612</b>
<b>I. Total liabilities</b>	<b>46,172</b>	<b>42,674</b>
<b>A. Noncontrolling interests</b>	<b>12,774</b>	<b>10,290</b>
Subscribed capital	563	558
Capital reserve	4,319	4,026
Other reserves	14,837	14,860
Accumulated other comprehensive income (loss)	1,663	-446
<b>B. Total Fresenius SE &amp; Co. KGaA shareholders' equity</b>	<b>21,382</b>	<b>18,998</b>
<b>II. Total shareholders' equity</b>	<b>34,156</b>	<b>29,288</b>
<b>Total liabilities and shareholders' equity</b>	<b>80,328</b>	<b>71,962</b>

The following notes are an integral part of the unaudited condensed interim financial statements.

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

€ in millions	Q1-3/2022	Q1-3/2021
<b>Operating activities</b>		
Net income	1,714	2,060
<b>Adjustments to reconcile net income to cash and cash equivalents provided by operating activities</b>		
Depreciation and amortization	2,147	1,922
Change in deferred taxes	-105	-34
Gain on sale of fixed assets and of investments and divestitures	-69	-26
<b>Changes in assets and liabilities, net of amounts from businesses acquired or disposed of</b>		
Trade accounts and other receivables	-570	-300
Inventories	-364	-180
Other current and non-current assets	-670	-217
Accounts receivable from/payable to related parties	-39	-32
Trade accounts payable, provisions and other short-term and long-term liabilities	210	44
Liabilities for income taxes	120	92
<b>Net cash provided by operating activities</b>	<b>2,374</b>	<b>3,329</b>
<b>Investing activities</b>		
Purchase of property, plant and equipment and capitalized development costs	-1,187	-1,371
Proceeds from sales of property, plant and equipment	15	28
Acquisitions and investments and purchases of intangible assets	-927	-764
Proceeds from sale of investments and divestitures	136	121
<b>Net cash used in investing activities</b>	<b>-1,963</b>	<b>-1,986</b>

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

€ in millions	Q1 – 3/2022	Q1 – 3/2021
<b>Financing activities</b>		
Proceeds from short-term debt	1,497	2,793
Repayments of short-term debt	-2,722	-551
Proceeds from long-term debt	1,557	501
Repayments of long-term debt	-655	-3,157
Repayments of lease liabilities	-716	-694
Proceeds from the issuance of bonds	1,300	2,714
Repayments of liabilities from bonds	-627	-1,535
Proceeds from the Accounts Receivable Facility of Fresenius Medical Care	24	0
Proceeds from the exercise of stock options	20	36
Dividends paid	-817	-991
Change in noncontrolling interests, net	-28	-11
<b>Net cash used in financing activities</b>	<b>-1,167</b>	<b>-895</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>120</b>	<b>128</b>
<b>Net decrease/increase in cash and cash equivalents</b>	<b>-636</b>	<b>576</b>
<b>Cash and cash equivalents at the beginning of the reporting period</b>	<b>2,764</b>	<b>1,837</b>
<b>Cash and cash equivalents at the end of the reporting period</b>	<b>2,128</b>	<b>2,413</b>

#### ADDITIONAL INFORMATION ON PAYMENTS THAT ARE INCLUDED IN NET CASH PROVIDED BY OPERATING ACTIVITIES

€ in millions	Q1 – 3/2022	Q1 – 3/2021
Received interest	85	63
Paid interest	-423	-377
Income taxes paid	-577	-552

The following notes are an integral part of the unaudited condensed interim financial statements.

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

	Subscribed Capital			Reserves	
	Number of ordinary shares in thousand	Amount € in thousands	Amount € in millions	Capital reserve € in millions	Other reserves € in millions
<b>As of December 31, 2020</b>	<b>557,541</b>	<b>557,541</b>	<b>557</b>	<b>3,992</b>	<b>13,535</b>
Proceeds from the exercise of stock options	913	913	1	31	
Compensation expense related to stock options				1	
Dividends paid					-491
Purchase of noncontrolling interests					
Put option liabilities					-11
Comprehensive income (loss)					
Net income					1,319
Other comprehensive income (loss)					
Cash flow hedges					
Change of FVOCI equity investments					
Foreign currency translation					
Actuarial gains on defined benefit pension plans					
Fair value changes					
Comprehensive income (loss)					1,319
<b>As of September 30, 2021</b>	<b>558,454</b>	<b>558,454</b>	<b>558</b>	<b>4,024</b>	<b>14,352</b>
<b>As of December 31, 2021</b>	<b>558,502</b>	<b>558,502</b>	<b>558</b>	<b>4,026</b>	<b>14,860</b>
Proceeds from the exercise of stock options	-	-	-	6	
Dividends paid					-367
Scrip dividend	4,735	4,735	5	142	-147
Transactions with noncontrolling interests without loss of control				145	
Noncontrolling interests due to changes in consolidation group					
Put option liabilities					-629
Transfer of cumulative gains/losses of equity investments					3
Comprehensive income (loss)					
Net income					1,117
Other comprehensive income (loss)					
Cash flow hedges					
Change of FVOCI equity investments					
Foreign currency translation					
Actuarial gains on defined benefit pension plans					
Fair value changes					
Comprehensive income (loss)					1,117
<b>As of September 30, 2022</b>	<b>563,237</b>	<b>563,237</b>	<b>563</b>	<b>4,319</b>	<b>14,837</b>

## FRESENIUS SE & CO. KGAA

### CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

	Accumulated other comprehensive income (loss)					Total Fresenius SE & Co. KGaA shareholders' equity € in millions	Noncontrolling interests € in millions	Total shareholders' equity € in millions
	Foreign currency translation € in millions	Cash flow hedges € in millions	Pensions € in millions	Equity investments € in millions	Fair value changes € in millions			
<b>As of December 31, 2020</b>	<b>-704</b>	<b>-62</b>	<b>-405</b>	<b>9</b>	<b>27</b>	<b>16,949</b>	<b>9,074</b>	<b>26,023</b>
Proceeds from the exercise of stock options						32	4	36
Compensation expense related to stock options						1	-	1
Dividends paid						-491	-500	-991
Purchase of noncontrolling interests						-	61	61
Put option liabilities						-11	-24	-35
Comprehensive income (loss)								
Net income						1,319	741	2,060
Other comprehensive income (loss)								
Cash flow hedges		-1				-1	0	-1
Change of FVOCI equity investments				-32		-32	21	-11
Foreign currency translation	517	0	-4	1	1	515	519	1,034
Actuarial gains on defined benefit pension plans			38			38	25	63
Fair value changes					-18	-18	-36	-54
Comprehensive income (loss)	517	-1	34	-31	-17	1,821	1,270	3,091
<b>As of September 30, 2021</b>	<b>-187</b>	<b>-63</b>	<b>-371</b>	<b>-22</b>	<b>10</b>	<b>18,301</b>	<b>9,885</b>	<b>28,186</b>
<b>As of December 31, 2021</b>	<b>54</b>	<b>-66</b>	<b>-411</b>	<b>-42</b>	<b>19</b>	<b>18,998</b>	<b>10,290</b>	<b>29,288</b>
Proceeds from the exercise of stock options						6	14	20
Dividends paid						-367	-513	-880
Scrip dividend						-	-	-
Transactions with noncontrolling interests without loss of control						145	369	514
Noncontrolling interests due to changes in consolidation group						-	609	609
Put option liabilities						-629	-337	-966
Transfer of cumulative gains/losses of equity investments				-3		-	-	-
Comprehensive income (loss)								
Net income						1,117	597	1,714
Other comprehensive income (loss)								
Cash flow hedges		1				1	1	2
Change of FVOCI equity investments				9		9	6	15
Foreign currency translation	1,815	-1	-9	0	0	1,805	1,607	3,412
Actuarial gains on defined benefit pension plans			300			300	139	439
Fair value changes					-3	-3	-8	-11
Comprehensive income (loss)	1,815	0	291	9	-3	3,229	2,342	5,571
<b>As of September 30, 2022</b>	<b>1,869</b>	<b>-66</b>	<b>-120</b>	<b>-36</b>	<b>16</b>	<b>21,382</b>	<b>12,774</b>	<b>34,156</b>

The following notes are an integral part of the unaudited condensed interim financial statements.

## FRESENIUS SE & CO. KGAA CONSOLIDATED SEGMENT REPORTING FIRST THREE QUARTERS (UNAUDITED)

by business segment, € in millions	Fresenius Medical Care			Fresenius Kabi			Fresenius Helios			Fresenius Vamed			Corporate			Fresenius Group		
	2022 <sup>2</sup>	2021 <sup>3</sup>	Growth	2022 <sup>4</sup>	2021 <sup>5</sup>	Growth	2022 <sup>5</sup>	2021 <sup>5</sup>	Growth	2022 <sup>6</sup>	2021	Growth	2022 <sup>7</sup>	2021 <sup>8</sup>	Growth	2022	2021	Growth
Sales	14,401	12,972	11%	5,814	5,370	8%	8,685	8,009	8%	1,647	1,549	6%	-350	-346	-1%	30,197	27,554	10%
thereof contribution to consolidated sales	14,353	12,938	11%	5,760	5,322	8%	8,668	7,990	8%	1,416	1,303	9%	0	1	-100%	30,197	27,554	10%
thereof intercompany sales	48	34	41%	54	48	13%	17	19	-11%	231	246	-6%	-350	-347	-1%	-	-	-
contribution to consolidated sales	47%	47%		19%	19%		29%	29%		5%	5%		0%	0%		100%	100%	
EBITDA	2,600	2,610	0%	1,172	1,194	-2%	1,205	1,134	6%	102	100	2%	-298	-81	--	4,781	4,957	-4%
Depreciation and amortization	1,278	1,187	8%	328	320	3%	374	346	8%	73	65	12%	94	4	--	2,147	1,922	12%
EBIT	1,322	1,423	-7%	844	874	-3%	831	788	5%	29	35	-17%	-392	-85	--	2,634	3,035	-13%
Net interest	-217	-214	-2%	-36	-48	25%	-134	-136	1%	-6	-7	14%	18	21	-14%	-375	-384	2%
Income taxes	-279	-279	0%	-182	-180	-1%	-153	-139	-10%	-5	-7	29%	74	14	--	-545	-591	8%
Net income attributable to shareholders of Fresenius SE & Co. KGaA	660	756	-13%	574	600	-4%	530	501	6%	15	18	-17%	-662	-556	-19%	1,117	1,319	-15%
Operating cash flow	1,568	1,820	-14%	543	868	-37%	411	595	-31%	-56	23	--	-92	23	--	2,374	3,329	-29%
Cash flow before acquisitions and dividends	1,082	1,259	-14%	221	494	-55%	84	254	-67%	-84	-34	-147%	-101	13	--	1,202	1,986	-39%
Total assets <sup>1</sup>	38,406	34,367	12%	17,747	14,698	21%	22,059	20,891	6%	3,002	2,795	7%	-886	-789	-12%	80,328	71,962	12%
Debt <sup>1</sup>	13,786	13,320	3%	4,531	4,159	9%	8,448	8,059	5%	911	721	26%	931	896	4%	28,607	27,155	5%
Other operating liabilities <sup>1</sup>	6,891	6,199	11%	4,092	3,250	26%	3,620	3,176	14%	1,014	994	2%	64	385	-83%	15,681	14,004	12%
Capital expenditure, gross	495	588	-16%	308	346	-11%	330	341	-3%	31	57	-46%	9	10	-10%	1,173	1,342	-13%
Acquisitions, gross/investments	136	366	-63%	723	1	--	81	438	-82%	15	1	--	-	1	-100%	955	807	18%
Research and development expenses	166	153	9%	422	443	-5%	2	2	0%	-	-		0	0		590	598	-1%
Employees (per capita on balance sheet date) <sup>1</sup>	130,295	130,251	0%	42,257	41,397	2%	125,977	123,484	2%	20,017	19,721	2%	1,145	1,225	-7%	319,691	316,078	1%
<b>Key figures</b>																		
EBITDA margin	18.1%	20.1%		20.2%	22.2%		13.9%	14.2%		6.2%	6.5%					16.6% <sup>9</sup>	18.2% <sup>5</sup>	
EBIT margin	9.2%	11.0%		14.5%	16.3%		9.6%	9.8%		1.8%	2.3%					9.8% <sup>9</sup>	11.2% <sup>5</sup>	
Depreciation and amortization in % of sales	8.9%	9.1%		5.6%	6.0%		4.3%	4.3%		4.4%	4.2%					7.1%	7.0%	
Operating cash flow in % of sales	10.9%	14.0%		9.3%	16.2%		4.7%	7.4%		-3.4%	1.5%					7.9%	12.1%	
ROOA <sup>1</sup>	5.1%	6.2%		7.9%	9.4%		5.8%	5.9%		3.9%	4.3%					5.7% <sup>10</sup>	6.5% <sup>11</sup>	

<sup>1</sup> 2021: December 31

<sup>2</sup> Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey, remeasurement Humacyte investment and net gain related to InterWell Health

<sup>3</sup> Before costs related to FME25 program

<sup>4</sup> Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey

<sup>5</sup> Before expenses associated with the Fresenius cost and efficiency program

<sup>6</sup> Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine

<sup>7</sup> After revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health

<sup>8</sup> After expenses associated with the Fresenius cost and efficiency program

<sup>9</sup> Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health

<sup>10</sup> The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties, remeasurement Humacyte investment and net gain related to InterWell Health.

<sup>11</sup> The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program.

The consolidated segment reporting is an integral part of the notes.



## FRESENIUS SE & CO. KGAA CONSOLIDATED SEGMENT REPORTING THIRD QUARTER (UNAUDITED)

by business segment, € in millions	Fresenius Medical Care			Fresenius Kabi			Fresenius Helios			Fresenius Vamed			Corporate			Fresenius Group		
	2022 <sup>1</sup>	2021 <sup>2</sup>	Growth	2022 <sup>3</sup>	2021 <sup>4</sup>	Growth	2022 <sup>4</sup>	2021 <sup>4</sup>	Growth	2022 <sup>5</sup>	2021	Growth	2022 <sup>6</sup>	2021 <sup>7</sup>	Growth	2022	2021	Growth
Sales	5,096	4,442	15%	2,071	1,854	12%	2,829	2,622	8%	572	516	11%	-109	-110	1%	10,459	9,324	12%
thereof contribution to consolidated sales	5,079	4,431	15%	2,053	1,838	12%	2,824	2,615	8%	504	440	15%	-1	0		10,459	9,324	12%
thereof intercompany sales	17	11	55%	18	16	13%	5	7	-29%	68	76	-11%	-108	-110	2%	-	-	
contribution to consolidated sales	48%	47%		20%	20%		27%	28%		5%	5%		0%	0%		100%	100%	
EBITDA	914	916	0%	397	414	-4%	348	341	2%	35	45	-22%	-36	-49	27%	1,658	1,667	-1%
Depreciation and amortization	444	403	10%	117	114	3%	126	119	6%	25	22	14%	59	1	--	771	659	17%
EBIT	470	513	-8%	280	300	-7%	222	222	0%	10	23	-57%	-95	-50	-90%	887	1,008	-12%
Net interest	-76	-69	-12%	-16	-15	-7%	-41	-47	13%	-3	-3	0%	-5	8	-163%	-141	-126	-12%
Income taxes	-108	-108	-2%	-62	-62	0%	-38	-37	-3%	-1	-5	80%	14	10	40%	-195	-201	3%
Net income attributable to shareholders of Fresenius SE & Co. KGaA	232	279	-17%	184	206	-11%	138	135	2%	5	14	-64%	-238	-222	-7%	321	413	-22%
Operating cash flow	658	691	-5%	301	393	-23%	353	157	125%	-18	9	--	-38	-24	-58%	1,256	1,226	2%
Cash flow before acquisitions and dividends	501	510	-2%	183	265	-31%	263	46	--	-28	-1	--	-43	-27	-59%	876	793	10%
Capital expenditure, gross	161	194	-18%	122	130	-6%	117	111	5%	11	10	10%	5	4	25%	416	449	-7%
Acquisitions, gross/investments	-14	156	-109%	501	-		6	9	-33%	9	1	--	-	1	-100%	502	167	--
Research and development expenses	61	52	17%	147	162	-9%	1	0		-	-		0	1	-100%	209	215	-3%
Key figures																		
EBITDA margin	17.9%	20.4%		19.2%	22.3%		12.3%	13.0%		6.1%	8.7%					15.9% <sup>8</sup>	18.3% <sup>4</sup>	
EBIT margin	9.2%	11.6%		13.5%	16.2%		7.8%	8.5%		1.7%	4.5%					9.1% <sup>8</sup>	11.2% <sup>4</sup>	
Depreciation and amortization in % of sales	8.7%	9.1%		5.6%	6.1%		4.5%	4.5%		4.4%	4.3%					7.4%	7.1%	
Operating cash flow in % of sales	12.9%	15.6%		14.5%	21.2%		12.5%	6.0%		-3.1%	1.7%					12.0%	13.1%	

<sup>1</sup> Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey and remeasurement Humacyte investment

<sup>2</sup> Before costs related to FME25 program

<sup>3</sup> Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey

<sup>4</sup> Before expenses associated with the Fresenius cost and efficiency program

<sup>5</sup> Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine

<sup>6</sup> After expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, remeasurement Humacyte investment and net gain related to InterWell Health

<sup>7</sup> After expenses associated with the Fresenius cost and efficiency program

<sup>8</sup> Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, remeasurement Humacyte investment and net gain related to InterWell Health

The consolidated segment reporting is an integral part of the notes.

## TABLE OF CONTENTS NOTES

### 43 General Notes

- 43 1. Principles
  - 43 I. Group structure
  - 43 II. Basis of presentation
  - 43 III. Summary of significant accounting policies
  - 45 IV. Recent pronouncements, applied
  - 45 V. Recent pronouncements, not yet applied
- 46 2. Acquisitions, divestitures and investments

### 50 Notes on the consolidated statement of income

- 50 3. Special items
- 50 4. Sales
- 51 5. Research and development expenses
- 51 6. Taxes
- 51 7. Earnings per share

### 52 Notes on the consolidated statement of financial position

- 52 8. Trade accounts and other receivables
- 52 9. Inventories
- 52 10. Other current and non-current assets
- 53 11. Goodwill
- 54 12. Debt
- 56 13. Bonds
- 57 14. Convertible bonds
- 57 15. Pensions and similar obligations
- 57 16. Noncontrolling interests
- 58 17. Fresenius SE & Co. KGaA shareholders' equity

### 60 Other notes

- 60 18. Legal and regulatory matters
- 62 19. Financial instruments
- 65 20. Information on capital management
- 65 21. Supplementary information on the consolidated statement of cash flows
- 66 22. Notes on the consolidated segment reporting
- 66 23. Share-based compensation plans
- 67 24. Subsequent events
- 67 25. Corporate Governance

## GENERAL NOTES

### 1. PRINCIPLES

#### I. GROUP STRUCTURE

Fresenius is a global healthcare group with products and services for dialysis, hospitals and outpatient medical care. In addition, the Fresenius Group focuses on hospital operations and also manages projects and provides services for hospitals and other healthcare facilities worldwide. Besides the activities of the parent company Fresenius SE & Co. KGaA, Bad Homburg v. d. H., Germany, the operating activities are organized amongst the following legally independent business segments as of September 30, 2022:

- ▶ Fresenius Medical Care
- ▶ Fresenius Kabi
- ▶ Fresenius Helios
- ▶ Fresenius Vamed

The reporting and functional currency of the Fresenius Group is the euro. In order to improve the clarity of presentation, amounts are generally presented in million euros. Amounts less than €1 million, after rounding, are marked with "0".

#### II. BASIS OF PRESENTATION

Fresenius SE & Co. KGaA, as a stock exchange listed company with a domicile in a member state of the European Union (EU), fulfills its obligation to prepare and publish the consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and applying Section 315e of the German Commercial Code (HGB).

The consolidated interim financial statements and accompanying condensed notes are prepared in accordance with the International Accounting Standard (IAS) 34. The primary financial statements are presented in the format consistent with the consolidated financial statements as of December 31, 2021. The consolidated interim financial statements have been prepared in accordance with the Standards and interpretations in effect on the reporting date, and endorsed in the EU, as issued by the International Accounting Standards Board (IASB) and the IFRS Interpretations Committee (IFRS IC).

The interim financial statements have been prepared in accordance with the same general accounting policies applied in the preparation of the consolidated financial statements as of December 31, 2021.

#### III. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

##### Principles of consolidation

The condensed consolidated financial statements and interim management report for the first three quarters and the third quarter ended September 30, 2022 have not been audited nor reviewed and should be read in conjunction with the notes included and published in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS as adopted by the EU.

Except for the reported acquisitions (see note 2, Acquisitions, divestitures and investments), there have been no other material changes in the Fresenius Group's consolidation structure.

The consolidated financial statements for the first three quarters and the third quarter ended September 30, 2022 include all adjustments that, in the opinion of the Management Board, are of a normal and recurring nature and are necessary to provide a fair presentation of the assets and liabilities, financial position and results of operations of the Fresenius Group.

The results of operations for the first three quarters and the third quarter ended September 30, 2022 are not necessarily indicative of the results of operations for the fiscal year 2022.

##### Classifications

Comparative information for certain items have been reclassified to conform with current year's presentation.

## Government grants and impacts of COVID-19 pandemic

In the first three quarters of 2022, the Fresenius Group received reimbursement payments and funding from various governments due to the COVID-19 pandemic. They have been accounted for in accordance with terms and regulations set forth in by the local laws and regulations.

In Germany, the hospitals of the Fresenius Group have received reimbursements and grants in the first three quarters of 2022 to compensate for COVID-19 related financial charges. In the first three quarters of 2022, the German hospitals of the Fresenius Group received total reimbursements and grants of €220 million (Q1–3/2021: €398 million), of which €195 million (Q1–3/2021: €369 million) were recorded in sales and €25 million (Q1–3/2021: €29 million) as grants in other operating income.

In the United States, Fresenius Medical Care North America received government grants from the U.S. government in the amount of €270 million (Q1–3/2021: €13 million). During the first three quarters of 2022, Fresenius Medical Care received an additional US\$234 million (€220 million) in U.S. Department of Health and Human Services funding available for healthcare providers affected by the COVID-19 pandemic. The remaining amount of government grants received recorded in deferred income was US\$9 million (€9 million) at September 30, 2022 and US\$62 million (€55 million) at December 31, 2021. The Fresenius Group

also recorded a contract liability for advance payments received under the Center for Medicare and Medicaid (CMS) Accelerated and Advance Payment program which is currently recorded within short-term provisions and other short-term liabilities. Contract liabilities related to the CMS Accelerated and Advance Payment program were US\$16 million (€16 million) and US\$443 million (€391 million) as of September 30, 2022 and December 31, 2021, respectively.

In addition to the programs above, the Fresenius Group also received grants and other reimbursements in the first three quarters of 2022 under various other programs from multiple governments around the world in the amount of €18 million (Q1–3/2021: €41 million).

## Hyperinflationary accounting

Fresenius Group's subsidiaries operating in Argentina, Lebanon and Turkey apply IAS 29, Financial Reporting in Hyperinflationary Economies, due to inflation in those countries. For the first three quarters of 2022, the application of IAS 29 resulted in an effect on net income attributable to shareholders of Fresenius SE & Co. KGaA of -€31 million (Q1–3/2021: -€12 million). The hyperinflationary accounting effects of the initial application on the opening consolidated statement of financial position in the amount of €29 million are presented within accumulated other comprehensive income (loss) related to foreign currency translation, and ongoing re-translation effects of comparative amounts are recorded in other comprehensive income (loss) within the consolidated financial statements.

## War in Ukraine

At the end of February 2022, Russia invaded Ukraine, triggering sanctions by various countries against Russia. The resulting uncertainties led to a further deterioration in the macroeconomic environment for the first three quarters of 2022, resulting in accelerating inflationary developments, significantly increased energy costs, supply chain disruptions and capital market volatility. These developments, combined with complications in the labor market in the United States faced by Fresenius Medical Care, created pressure on Fresenius Group's operations. The Fresenius Group continues to monitor the situation. As of September 30, 2022, the Fresenius Group's assets in Russia and Ukraine totaled less than 1% of Fresenius Group's total assets.

## Use of estimates

The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

#### IV. RECENT PRONOUNCEMENTS, APPLIED

The Fresenius Group has prepared its consolidated financial statements at and for the six months ended September 30, 2022 in conformity with IFRS, as adopted by the EU, that must be applied for the interim periods starting on or after January 1, 2022.

For the first three quarters of 2022, there were no recently implemented accounting pronouncements that had a material effect on the Fresenius Group's consolidated financial statements.

#### V. RECENT PRONOUNCEMENTS, NOT YET APPLIED

The IASB issued the following new standards relevant for the Fresenius Group's business:

In January 2020, the IASB issued **Amendments to IAS 1, Classification of Liabilities as Current and Non-current**. The amendments clarify under which circumstances debt and other liabilities with an uncertain settlement date should be classified as current or non-current. Among others, the amendments state that liabilities shall be classified depending on rights that exist at the end of the reporting period and define under which conditions liabilities might be settled by cash, other economic resources or equity. On July 15, 2020, the IASB deferred the effective date by one year to provide companies with more time to implement any classification changes resulting from the amendments. The amendments to IAS 1 are now effective

for fiscal years beginning on or after January 1, 2023. Earlier adoption is permitted. The Fresenius Group is currently evaluating the impact of the amendments to IAS 1 on the consolidated financial statements.

In May 2017, the IASB issued **IFRS 17, Insurance Contracts**. In June 2020 and December 2021, further amendments were published. IFRS 17 establishes principles for the recognition, measurement, presentation and disclosure related to the issuance of insurance contracts. IFRS 17 replaces IFRS 4, Insurance Contracts, which was brought in as an interim standard in 2004. IFRS 4 permitted the use of national accounting standards for the accounting of insurance contracts under IFRS. As a result of the varied application for insurance contracts, there was a lack of comparability among peer groups. IFRS 17 eliminates this diversity in practice by requiring all insurance contracts to be accounted for using updated estimates and assumptions that reflect the timing of cash flows and any uncertainty relating to insurance contracts.

The Fresenius Group does not expect that IFRS 17 will have a material impact on its consolidated financial statements and will continue to assess the qualitative and quantitative impacts of the application of IFRS 17.

Based on an assessment performed during 2022, the Fresenius Group believes that the premium allocation approach under IFRS 17 is the most appropriate measurement model. On initial recognition of the liability for incurred claims, the estimation and valuation process remains unchanged as compared to the application of IFRS 4.

Regarding the measurement of the liability for the remaining coverage, the liability is equal to the premiums received less any insurance acquisition cash flows. The Fresenius Group does not consider the effects and time value of money when measuring the liability for the remaining coverage, as the related cash flow is expected to be paid or received in one year or less from the date the claims are incurred. The Fresenius Group will apply the modified retrospective approach at the transition. Insurance premium revenues are currently recognized based on the passage of time, therefore the pattern of revenue recognition will not change upon the application of IFRS 17.

On June 25, 2020, the IASB issued amendments to IFRS 17, which among others, defer the effective date to fiscal years beginning on or after January 1, 2023. Earlier adoption is permitted for entities that have also adopted IFRS 9, Financial Instruments, and IFRS 15, Revenue from Contracts with Customers.

The EU Commission's endorsement of the amendments to IAS 1 is still outstanding.

In the Fresenius Group's view, there are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the consolidated financial statements.

## 2. ACQUISITIONS, DIVESTITURES AND INVESTMENTS

The Fresenius Group made acquisitions, investments and purchases of intangible assets of €955 million and €807 million in the first three quarters of 2022 and 2021, respectively. Of this amount, €927 million was paid in cash and €28 million was assumed obligations in the first three quarters of 2022.

### FRESENIUS MEDICAL CARE

In the first three quarters of 2022, Fresenius Medical Care spent €136 million (Q1–3 / 2021: €366 million) on acquisitions, mainly on the purchase of dialysis clinics.

#### Acquisition InterWell Health

On August 24, 2022 (acquisition date), Fresenius Medical Care completed a business combination among Fresenius Health Partners, Inc. (FHP), the value-based care division of Fresenius Medical Care's wholly owned subsidiary Fresenius Medical Care Holdings, Inc., with InterWell Health LLC, a physician organization driving innovation in the kidney care space in the United States, and Cricket Health, Inc., a U.S. provider of value-based kidney care

with a patient engagement and data platform. The transaction was completed after regulatory approval was received in the United States and other customary closing conditions were satisfied. Upon completion of the transactions with noncontrolling shareholders and consummation of the business combination described below, Fresenius Medical Care held approximately 75% of the new company. The new company, InterWell Topco L.P. (NewCo), will operate under the InterWell Health brand and will target the management of care for more than 270,000 people with kidney disease.

Under the terms and conditions of this business combination, Cricket Health, Inc. contributed all of its net assets in exchange for approximately 17% of the equity interest in NewCo. The fair value of the consideration transferred by Fresenius Medical Care to Cricket Health, Inc. for a controlling interest in NewCo was US\$269 million (€271 million as of the acquisition date).

InterWell Health LLC also contributed all of its net assets in exchange for approximately 8% of the equity interest in NewCo. The fair value of the consideration transferred by Fresenius Medical Care to InterWell Health LLC for a controlling interest in NewCo was US\$137 million (€138 million as of the acquisition date). Prior to the transaction, Fresenius Medical Care owned approximately 46%

of InterWell Health LLC with a carrying value of US\$19 million (€19 million) and a fair value of US\$176 million (€176 million) as of the acquisition date. At the acquisition date, Fresenius Medical Care received approximately 7% equity in NewCo in exchange for its investment in InterWell Health, LLC. As a result of the transaction, Fresenius Medical Care recognized a remeasurement gain of US\$156 million (€147 million), which represented the difference between the fair value and the carrying value of its investment in InterWell Health LLC prior to the acquisition date, and a related currency translation adjustment reversal due to the disposal of its investment in InterWell Health LLC in the amount of €364 thousand. The remeasurement gain is recorded in the consolidated statement of income within selling, general and administrative expenses.

The contributions of the net assets of InterWell Health LLC and Cricket Health, Inc. were accounted for as a business combination in accordance with IFRS 3 in which Fresenius Medical Care was identified as the acquirer and InterWell Health LLC and Cricket Health, Inc. were identified as acquired companies. NewCo has been consolidated in Fresenius Medical Care's consolidated financial statements as of and for the reporting period ending September 30, 2022.

Fresenius Medical Care also contributed the business of FHP in exchange for approximately 68% of equity interest in NewCo. Since Fresenius Medical Care controlled FHP before the acquisition date and controls NewCo post-acquisition date, Fresenius Medical Care's contribution of FHP was accounted for as an equity transaction. Therefore, the net assets contributed were recorded at their respective carrying value at the acquisition date. Noncontrolling interest was recognized in the amount of US\$5 million (€5 million as of the acquisition date) and additional paid in capital of US\$401 million (€404 million as of the acquisition date) representing the difference between the carrying value and the fair value of the corresponding interests was recorded within the line item transactions with noncontrolling interests without loss of control in the consolidated statement of changes in shareholders' equity.

As a result of the transaction, Fresenius Medical Care recorded additional noncontrolling interests at fair value in the amount of US\$194 million (€195 million as of the acquisition date) using the full goodwill method within the line item noncontrolling interests due to changes in consolidation group in the consolidated statement of changes in shareholders' equity. A third party valuation advisor was engaged to assist Fresenius Medical Care in the estimation of the underlying fair value of the transaction and primarily

employed an income approach which was used in the calculation of consideration transferred to the acquirees as well as in the calculation of noncontrolling interests. In addition, Fresenius Medical Care also granted put options to noncontrolling shareholders with an estimated fair value of US\$577 million (€592 million) at September 30, 2022 (as of acquisition date: US\$604 million (€608 million)). The fair value was determined on the basis of independent valuations.

The following allocation of the purchase price is based upon information available to management as of September 30, 2022. Based on a preliminary allocation, the following assets, including goodwill (which will not be deductible for tax purposes), were acquired and liabilities were assumed as of the acquisition date:

	US\$ in millions	in Mio €
<b>Fair values of assets acquired and liabilities assumed</b>		
Cash and cash equivalents	57	58
Other assets	3	3
Intangible assets	35	35
Goodwill	703	708
Other liabilities	-13	-13
Deferred tax liabilities	-9	-9
Noncontrolling interests	-194	-195
<b>Transferred consideration</b>	<b>582</b>	<b>585</b>
thereof fair value of consideration transferred	406	409
thereof fair value of previously held equity method investment in InterWell Health LLC	176	176

Fresenius Medical Care is in the process of obtaining and evaluating the information necessary for the purchase price allocations, including, but not limited to, working capital, tax-related items and the final capital interest allocation. As such, the balances noted in the table above are provisional and subject to measurement period adjustments permitted under IFRS 3. Any adjustments to acquisition accounting, net of related income tax effects, will be recorded with a corresponding adjustment to goodwill within one year from the acquisition date.

As of the acquisition date, amortizable intangible assets, primarily a technology platform, in the amount of US\$35 million (€35 million) acquired in this transaction have weighted average useful lives of 12 years.

As of the acquisition date, goodwill in the amount of US\$703 million (€708 million) was recorded as part of the transaction and mainly represents anticipated synergies and future cash flows expected to be generated by NewCo. The entire amount of goodwill recorded as a result of this transaction was allocated to the North America cash generating unit.

Additionally, and as contemplated in the agreement, Fresenius Medical Care also transferred Acumen Physician Solutions, LLC (Acumen) to NewCo shortly after the acquisition date, and prior to September 30, 2022, with working capital in the amount of US\$2 million (€2 million as of the date of the transfer agreement). Since certain long-lived assets (mainly intangible assets) held by Acumen will be

utilized materially differently by NewCo, management performed an impairment assessment prior to the transfer, concluded that the assets were completely impaired and recorded an impairment charge in the North America Segment in the amount of US\$71 million before the transfer (€67 million). Fresenius Medical Care also incurred certain transaction-related costs of US\$25 million (€24 million). The expenses, along with the impairment charges were recognized in selling, general and administrative expenses in the consolidated statement of income.

From August 24, 2022 through September 30, 2022, the revenue contributed by the acquired companies (i.e. Cricket Health, Inc. and InterWell Health LLC) was not material. During this period, Fresenius Medical Care recognized a loss of €4 million from the acquired companies within its consolidated profit or loss.

### FRESENIUS KABI

In the first three quarters of 2022, Fresenius Kabi spent €723 million (Q1 – 3 / 2021: €1 million) on acquisitions, mainly for the acquisition of a stake of 55% of mAbxience Holding S.L. and for the acquisition of 100% of the shares of Ivenix, Inc.

### Acquisition mAbxience

On August 1, 2022, Fresenius Kabi closed the acquisition of a stake of 55% of mAbxience Holding S.L. (mAbxience), a leading international biopharmaceutical company, focused on the rapidly growing market for the development and manufacturing of biological drugs (biopharmaceuticals). The additional production capacities are expected to generate significant cost synergies in the longer term with regard to the company's own biosimilars portfolio. At the time of the acquisition, the company employed 734 staff and generated sales of €252 million in 2021. mAbxience has been consolidated since August 1, 2022.

The consideration transferred in the amount of €510 million is a combination of €498 million upfront payment, which was paid in cash upon closing, and performance-based payments expected for future years with a current fair value of €12 million. These are strictly tied to the achievement of development and operating targets. The contractual provisions also include a put/call option scheme regarding the current owners' remaining shares in mAbxience (45%). The exercise price of the put/call options is based on fair values estimated by means of independent valuations. The fair value recognized was determined using a discounted cash flow model. A corresponding liability of €464 million was accounted for in the consolidated statement of financial position under other long-term liabilities.

The transaction was accounted for as a business combination. Noncontrolling interests were recognized at fair value using the full goodwill method and reported within the noncontrolling interests due to changes in consolidation group in the consolidated statement of changes in equity.

The following table summarizes the present estimated fair values of assets acquired and liabilities assumed at the date of the acquisition. The allocation of the purchase price is based upon the best information available to management at present. Due to the relatively short time frame between closing of the acquisition and the date of the statement of financial position, certain information may be incomplete. Any adjustments to acquisition accounting, net of related income tax effects, will be recorded with a corresponding adjustment to goodwill.

€ in millions	
<b>Fair values of assets acquired and liabilities assumed</b>	
Cash and cash equivalents	6
Trade accounts and other receivables	25
Inventories	90
Other current assets	27
Property, plant and equipment	68
Intangible assets and other assets	424
Goodwill	452
Trade accounts payable, short-term provisions and other short-term liabilities	-41
Other liabilities	-124
Noncontrolling interests	-417
<b>Transferred consideration</b>	<b>510</b>



The goodwill in the amount of €452 million resulting from the acquisition is not deductible for tax purposes and is allocated to the four cash generating units of Fresenius Kabi according to the regional distribution of the acquired business.

Goodwill mainly represents the value of future opportunities arising from the acquisition of the biosimilars molecules and the related expansion of Fresenius Kabi's biosimilars platform as well as from expected cost synergies from the use of the acquired production capacities for the existing biosimilars portfolio.

Intangible assets mainly relate to the value of the acquired biosimilars molecules, some of which are still in development.

mAbxience has contributed €21 million to sales and -€8 million to the operating income (EBIT) of the Fresenius Group since August 1, 2022.

### Acquisition Ivenix

On May 3, 2022, Fresenius Kabi closed the acquisition of 100% of the shares of Ivenix, Inc. (Ivenix), a specialized infusion therapy company. The cash purchase price is a combination of US\$240 million (€228 million) upfront payment and milestone payments in the lower three-digit million euro range, strictly linked to the achievement of commercial and operating targets.

The transaction was accounted for as a business combination.

Based on the preliminary purchase price allocation, a goodwill of US\$199 million (€188 million) and intangible assets in the amount of US\$180 million (€171 million) were recorded for the initial statement of financial position. Goodwill primarily represents the value of future opportunities arising from the additional growth potential, the profitability development planned as a result of the production shift, and the economies of scale and scope in infusion therapy.

Intangible assets mainly relate to the acquired technology.

### FRESENIUS HELIOS

In the first three quarters of 2022, Fresenius Helios spent €81 million (Q1–3 / 2021: €438 million) on acquisitions, mainly for the purchase of an oncology clinic and an ophthalmology care center in Colombia as well as the acquisition of a clinic in Spain.

### FRESENIUS VAMED

In the first three quarters of 2022, Fresenius Vamed spent €15 million (Q1–3 / 2021: €0 million) on acquisitions, mainly for the purchase of two rehabilitation clinics in Germany and one in the United Kingdom.

## NOTES ON THE CONSOLIDATED STATEMENT OF INCOME

### 3. SPECIAL ITEMS

Net income attributable to shareholders of Fresenius SE & Co. KGaA for the first three quarters of 2022 in the amount of €1,117 million includes special items relating to the Fresenius cost and efficiency program (including the FME25 program), impacts related to the war in Ukraine, the remeasurement of the Humacyte investment, the net gain related to InterWell Health, transaction costs for mAbxience and Ivenix, hyperinflation Turkey, retroactive duties and the revaluation of biosimilars contingent purchase price liabilities.

The special items had the following impact on the consolidated statement of income of the first three quarters of 2022:

€ in millions	EBIT	Interest expenses	Net income attributable to shareholders of Fresenius SE & Co. KGaA
<b>Earnings Q1 – 3/2022, before special items</b>	<b>2,952</b>	<b>-376</b>	<b>1,284</b>
Expenses associated with the Fresenius cost and efficiency program (including the FME25 program)	-211	–	-109
Impacts related to the war in Ukraine	-44	–	-24
Remeasurement Humacyte investment	-79	–	-18
Transaction costs mAbxience, Ivenix	-22	–	-17
Hyperinflation Turkey	-11	–	-7
Retroactive duties	-9	–	-6
Revaluations of biosimilars contingent purchase price liabilities	2	1	2
Net gain related to InterWell Health	56	–	12
<b>Earnings Q1 – 3/2022 according to IFRS</b>	<b>2,634</b>	<b>-375</b>	<b>1,117</b>

Net income attributable to shareholders of Fresenius SE & Co. KGaA for the first three quarters of 2021 in the amount of €1,319 million included special items relating to the Fresenius cost and efficiency program (including the FME25 program).

The special items had the following impact on the consolidated statement of income of the first three quarters of 2021:

€ in millions	EBIT	Interest expenses	Net income attributable to shareholders of Fresenius SE & Co. KGaA
<b>Earnings Q1 – 3/2021, before special items</b>	<b>3,086</b>	<b>-384</b>	<b>1,346</b>
Expenses associated with the Fresenius cost and efficiency program (including the FME25 program)	-51	–	-27
<b>Earnings Q1 – 3/2021 according to IFRS</b>	<b>3,035</b>	<b>-384</b>	<b>1,319</b>

### 4. SALES

Sales by activity were as follows:

€ in millions	Q1 – 3/2022					Fresenius Group
	Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed	Corporate	
Sales from contracts with customers	13,909	5,756	8,660	1,413	0	29,738
thereof sales of services	11,106	60	8,650	1,033	0	20,849
thereof sales of products and related services	2,803	5,688	–	–	–	8,491
thereof sales from long-term production contracts	–	–	–	380	–	380
thereof further sales from contracts with customers	–	8	10	–	–	18
Other sales	444	4	8	3	–	459
<b>Sales</b>	<b>14,353</b>	<b>5,760</b>	<b>8,668</b>	<b>1,416</b>	<b>0</b>	<b>30,197</b>

€ in millions	Q1 – 3/2021					Fresenius Group
	Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed	Corporate	
Sales from contracts with customers	12,558	5,320	7,981	1,300	1	27,160
thereof sales of services	9,963	57	7,972	948	1	18,941
thereof sales of products and related services	2,595	5,255	–	–	–	7,850
thereof sales from long-term production contracts	–	–	–	352	–	352
thereof further sales from contracts with customers	–	8	9	–	–	17
Other sales	380	2	9	3	–	394
<b>Sales</b>	<b>12,938</b>	<b>5,322</b>	<b>7,990</b>	<b>1,303</b>	<b>1</b>	<b>27,554</b>

Other sales include sales from insurance and lease contracts.

## 5. RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses of €590 million (Q1 – 3 / 2021: €598 million) included expenditures for research and non-capitalizable development costs as well as regular depreciation and amortization expenses relating to capitalized development costs of €21 million (Q1 – 3 / 2021: €16 million). The expenses for the further development of the biosimilars business included in the research and development expenses amounted to €114 million in the first three quarters of 2022 (Q1 – 3 / 2021: €123 million).

## 6. TAXES

During the first three quarters of 2022, there were no material changes relating to accruals for income taxes as well as recognized and accrued payments for interest and penalties. Further information can be found in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.

## 7. EARNINGS PER SHARE

The following table shows the earnings per share including and excluding the dilutive effect from stock options issued:

	Q1 – 3/2022	Q1 – 3/2021
<b>Numerators, € in millions</b>		
Net income attributable to shareholders of Fresenius SE & Co. KGaA	1,117	1,319
less effect from dilution due to Fresenius Medical Care shares	–	0
Income available to all ordinary shares	1,117	1,319
<b>Denominators in number of shares</b>		
Weighted average number of ordinary shares outstanding	560,606,647	557,920,123
Potentially dilutive ordinary shares	–	128,220
Weighted average number of ordinary shares outstanding assuming dilution	560,606,647	558,048,343
<b>Basic earnings per share in €</b>	<b>1.99</b>	<b>2.36</b>
<b>Fully diluted earnings per share in €</b>	<b>1.99</b>	<b>2.36</b>

## NOTES ON THE CONSOLIDATED STATEMENT OF FINANCIAL POSITION

### 8. TRADE ACCOUNTS AND OTHER RECEIVABLES

As of September 30, 2022 and December 31, 2021, trade accounts and other receivables were as follows:

€ in millions	September 30, 2022		December 31, 2021	
		thereof credit impaired		thereof credit impaired
Trade accounts and other receivables	8,491	817	7,494	691
less allowances for expected credit losses	514	370	449	340
<b>Trade accounts and other receivables, net</b>	<b>7,977</b>	<b>447</b>	<b>7,045</b>	<b>351</b>

Within trade accounts and other receivables (before allowances) as of September 30, 2022, €8,287 million (December 31, 2021: €7,378 million) relate to revenue from contracts with customers as defined by IFRS 15. This amount includes €512 million (December 31, 2021: €448 million) of allowances for expected credit losses. Further trade accounts and other receivables, net, relate to other sales.

### 9. INVENTORIES

As of September 30, 2022 and December 31, 2021, inventories consisted of the following:

€ in millions	Sept. 30, 2022	Dec. 31, 2021
Raw materials and purchased components	1,219	971
Work in process	533	440
Finished goods	3,417	2,961
less reserves	170	154
<b>Inventories, net</b>	<b>4,999</b>	<b>4,218</b>

### 10. OTHER CURRENT AND NON-CURRENT ASSETS

At equity investments as of September 30, 2022 in the amount of €786 million (December 31, 2021: €804 million) mainly related to the equity method investee of Fresenius Medical Care named Vifor Fresenius Medical Care Renal Pharma Ltd. In the first three quarters of 2022, income of €47 million (Q1 – 3 / 2021: €71 million) resulting from this equity investment was included in selling, general and administrative expenses in the consolidated statement of income.

## 11. GOODWILL

The carrying amount of goodwill has developed as follows:

€ in millions	Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed	Corporate	Fresenius Group
<b>Carrying amount as of January 1, 2021</b>	<b>12,959</b>	<b>5,058</b>	<b>8,278</b>	<b>298</b>	<b>6</b>	<b>26,599</b>
Additions	444	-	621	0	-	1,065
Disposals	-	-1	0	-	-	-1
Foreign currency translation	958	316	4	2	-	1,280
<b>Carrying amount as of December 31, 2021</b>	<b>14,361</b>	<b>5,373</b>	<b>8,903</b>	<b>300</b>	<b>6</b>	<b>28,943</b>
Additions	684	639	152	13	-	1,488
Disposals	-	-	-2	-	-	-2
Foreign currency translation	2,142	669	25	-	-	2,836
<b>Carrying amount as of September 30, 2022</b>	<b>17,187</b>	<b>6,681</b>	<b>9,078</b>	<b>313</b>	<b>6</b>	<b>33,265</b>

The increase of goodwill relates to the acquisitions from Fresenius Kabi (mainly mAbxience and Ivenix) and Fresenius Medical Care (mainly InterWell Health) as well as foreign currency translation.

## 12. DEBT

### SHORT-TERM DEBT

As of September 30, 2022 and December 31, 2021, short-term debt consisted of the following:

€ in millions	Book value	
	September 30, 2022	December 31, 2021
Fresenius SE & Co. KGaA Commercial Paper	625	1,056
Fresenius Medical Care AG & Co. KGaA Commercial Paper	412	715
Other short-term debt	571	1,070
<b>Short-term debt</b>	<b>1,608</b>	<b>2,841</b>

### LONG-TERM DEBT

As of September 30, 2022 and December 31, 2021, long-term debt net of debt issuance costs consisted of the following:

€ in millions	Book value	
	September 30, 2022	December 31, 2021
Schuldschein Loans	1,596	1,757
Loan from the European Investment Bank	400	-
Accounts Receivable Facility of Fresenius Medical Care	26	-
Other	849	843
<b>Subtotal</b>	<b>2,871</b>	<b>2,600</b>
less current portion	528	473
<b>Long-term debt, less current portion</b>	<b>2,343</b>	<b>2,127</b>

## Schuldschein Loans

As of September 30, 2022 and December 31, 2021, Schuldschein Loans of the Fresenius Group net of debt issuance costs consisted of the following:

	Notional amount	Maturity	Interest rate fixed/variable	Book value € in millions	
				Sept. 30, 2022	Dec. 31, 2021
Fresenius SE & Co. KGaA 2017/2022	€372 million	Jan. 31, 2022	0.93% / variable	–	372
Fresenius SE & Co. KGaA 2015/2022	€21 million	April 7, 2022	1.61%	–	21
Fresenius SE & Co. KGaA 2019/2023	€378 million	Sept. 25, 2023	0.55% / variable	378	378
Fresenius SE & Co. KGaA 2017/2024	€421 million	Jan. 31, 2024	1.40% / variable	421	421
Fresenius SE & Co. KGaA 2019/2026	€238 million	Sept. 23, 2026	0.85% / variable	238	238
Fresenius SE & Co. KGaA 2017/2027	€207 million	Jan. 29, 2027	1.96% / variable	206	206
Fresenius SE & Co. KGaA 2019/2029	€84 million	Sept. 24, 2029	1.10%	84	84
Fresenius US Finance II, Inc. 2016/2023	US\$43 million	March 10, 2023	3.12%	44	37
Fresenius Medical Care AG & Co. KGaA 2022/2027	€25 million	Feb. 14, 2027	variable	25	–
Fresenius Medical Care AG & Co. KGaA 2022/2029	€200 million	Feb. 14, 2029	variable	200	–
<b>Schuldschein Loans</b>				<b>1,596</b>	<b>1,757</b>

On February 14, 2022, Fresenius Medical Care AG & Co. KGaA issued €225 million of Schuldschein Loans in two tranches at variable interest rates with maturities of five and seven years. The proceeds were used for general corporate purposes including refinancing of existing financial liabilities.

As of September 30, 2022, the Schuldschein Loan of Fresenius US Finance II, Inc. in the amount of US\$43 million due on March 10, 2023 and the Schuldschein Loan of Fresenius SE & Co. KGaA in the amount of €378 million due on September 25, 2023, are shown as current portion of long-term debt in the consolidated statement of financial position.

### Loan from the European Investment Bank

On January 31, 2022, Fresenius SE & Co. KGaA drew a loan from the European Investment Bank in the amount of €400 million with variable interest rates which is due on December 15, 2025.

### CREDIT LINES AND OTHER SOURCES OF LIQUIDITY

The syndicated credit facilities of Fresenius SE & Co. KGaA and Fresenius Medical Care AG & Co. KGaA in the amount of €2.0 billion each which were entered into in July 2021 serve as backup line. On June 8, 2022, both syndicated credit facilities were amended and extended to extend the

term by one year and replace U.S. dollar LIBOR as the reference rate with the Term Secured Overnight Financing Rate. They were undrawn as of September 30, 2022. In addition, further bilateral facilities are available to the Fresenius Group which have not been utilized, or have only been utilized in part, as of the reporting date.

At September 30, 2022, the available borrowing capacity resulting from unutilized credit facilities was approximately €6.2 billion. Thereof, €4.0 billion accounted for syndicated credit facilities and approximately €2.2 billion for bilateral facilities with commercial banks.

### 13. BONDS

As of September 30, 2022 and December 31, 2021, bonds of the Fresenius Group net of debt issuance costs consisted of the following:

	Notional amount	Maturity	Interest rate	Book value € in millions	
				September 30, 2022	December 31, 2021
Fresenius Finance Ireland PLC 2017/2024	€700 million	Jan. 30, 2024	1.50%	699	699
Fresenius Finance Ireland PLC 2021/2025	€500 million	Oct. 1, 2025	0.00%	497	497
Fresenius Finance Ireland PLC 2017/2027	€700 million	Feb. 1, 2027	2.125%	696	695
Fresenius Finance Ireland PLC 2021/2028	€500 million	Oct. 1, 2028	0.50%	497	497
Fresenius Finance Ireland PLC 2021/2031	€500 million	Oct. 1, 2031	0.875%	495	494
Fresenius Finance Ireland PLC 2017/2032	€500 million	Jan. 30, 2032	3.00%	496	496
Fresenius SE & Co. KGaA 2014/2024	€450 million	Feb. 1, 2024	4.00%	450	449
Fresenius SE & Co. KGaA 2019/2025	€500 million	Feb. 15, 2025	1.875%	498	497
Fresenius SE & Co. KGaA 2022/2025	€750 million	May 24, 2025	1.875%	745	-
Fresenius SE & Co. KGaA 2020/2026	€500 million	Sep. 28, 2026	0.375%	496	495
Fresenius SE & Co. KGaA 2020/2027	€750 million	Oct. 8, 2027	1.625%	743	742
Fresenius SE & Co. KGaA 2020/2028	€750 million	Jan. 15, 2028	0.75%	745	745
Fresenius SE & Co. KGaA 2019/2029	€500 million	Feb. 15, 2029	2.875%	496	495
Fresenius SE & Co. KGaA 2022/2030	€550 million	May 24, 2030	2.875%	545	-
Fresenius SE & Co. KGaA 2020/2033	€500 million	Jan. 28, 2033	1.125%	497	497
Fresenius US Finance II, Inc. 2015/2023	US\$300 million	Jan. 15, 2023	4.50%	308	265
Fresenius Medical Care AG & Co. KGaA 2019/2023	€650 million	Nov. 29, 2023	0.25%	649	649
Fresenius Medical Care AG & Co. KGaA 2018/2025	€500 million	July 11, 2025	1.50%	498	498
Fresenius Medical Care AG & Co. KGaA 2020/2026	€500 million	May 29, 2026	1.00%	497	496
Fresenius Medical Care AG & Co. KGaA 2019/2026	€600 million	Nov. 30, 2026	0.625%	596	595
Fresenius Medical Care AG & Co. KGaA 2022/2027	€750 million	Sep. 20, 2027	3.875%	745	-
Fresenius Medical Care AG & Co. KGaA 2019/2029	€500 million	Nov. 29, 2029	1.25%	498	497
Fresenius Medical Care AG & Co. KGaA 2020/2030	€750 million	May 29, 2030	1.50%	746	746
Fresenius Medical Care US Finance II, Inc. 2012/2022	US\$700 million	Jan. 31, 2022	5.875%	-	618
Fresenius Medical Care US Finance II, Inc. 2014/2024	US\$400 million	Oct. 15, 2024	4.75%	409	352
Fresenius Medical Care US Finance III, Inc. 2019/2029	US\$500 million	June 15, 2029	3.75%	505	434
Fresenius Medical Care US Finance III, Inc. 2020/2031	US\$1,000 million	Feb. 16, 2031	2.375%	1,018	875
Fresenius Medical Care US Finance III, Inc. 2021/2026	US\$850 million	Dec. 1, 2026	1.875%	865	744
Fresenius Medical Care US Finance III, Inc. 2021/2031	US\$650 million	Dec. 1, 2031	3.00%	659	567
<b>Bonds</b>				<b>16,588</b>	<b>14,634</b>

On September 20, 2022, Fresenius Medical Care AG & Co. KGaA placed bonds with an aggregate volume of €750 million with a maturity of five years.

On May 24, 2022, Fresenius SE & Co. KGaA placed bonds with an aggregate volume of €1,300 million. The bonds consist of two tranches with maturities of three and eight years.

As of September 30, 2022, the bonds issued by Fresenius US Finance II, Inc. in the amount of US\$300 million, which are due on January 15, 2023, are shown as current portion of bonds in the consolidated statement of financial position.



## 14. CONVERTIBLE BONDS

As of September 30, 2022 and December 31, 2021, the convertible bonds of the Fresenius Group net of debt issuance costs consisted of the following:

	Notional amount	Maturity	Coupon	Current conversion price	Book value € in millions	
					September 30, 2022	December 31, 2021
Fresenius SE & Co. KGaA 2017/2024	€500 million	Jan. 31, 2024	0.000%	€104.2835	488	482
<b>Convertible bonds</b>					<b>488</b>	<b>482</b>

The fair value of the derivative embedded in the convertible bonds of Fresenius SE & Co. KGaA was €13 thousand and €70 thousand at September 30, 2022 and December 31, 2021, respectively. Fresenius SE & Co. KGaA purchased stock options (call options) with a corresponding fair value to hedge future fair value fluctuations of this derivative.

Potential conversions are always cash-settled. Any increase of Fresenius' share price above the conversion price would be offset by a corresponding value increase of the call options.

## 15. PENSIONS AND SIMILAR OBLIGATIONS

Long-term pension liabilities decreased by €551 million from €1,675 million at December 31, 2021 to €1,124 million at September 30, 2022. This is mainly attributable to adjustments to the discount rate, which resulted in an actuarial gain of the same amount to be recognized in other comprehensive income (loss). For the German "Versorgungsordnung der Fresenius-Unternehmen", which accounts for the substantial portion of the pension liabilities at approximately 80%, a discount rate of 4.20% was applied as of September 30, 2022 (December 31, 2021: 1.40%).

## 16. NONCONTROLLING INTERESTS

As of September 30, 2022 and December 31, 2021, noncontrolling interests in the Fresenius Group were as follows:

€ in millions	Sept. 30, 2022	Dec. 31, 2021
Noncontrolling interests in Fresenius Medical Care AG & Co. KGaA	10,209	8,609
Noncontrolling interests in VAMED Aktiengesellschaft	85	88
Noncontrolling interests in the business segments		
Fresenius Medical Care	1,684	1,280
Fresenius Kabi	611	161
Fresenius Helios	166	134
Fresenius Vamed	19	18
<b>Total noncontrolling interests</b>	<b>12,774</b>	<b>10,290</b>

The increase of noncontrolling interests of Fresenius Medical Care mainly relates to currency translation and the InterWell Health acquisition.

The increase of noncontrolling interests of Fresenius Kabi mainly results from the acquisition of a stake of 55% of mAbxience.

Noncontrolling interests changed as follows:

€ in millions	Q1 - 3/2022
<b>Noncontrolling interests as of December 31, 2021</b>	<b>10,290</b>
Noncontrolling interests in profit	597
Purchase of noncontrolling interests	609
Stock options	14
Dividend payments	-513
Share buy-back program of Fresenius Medical Care AG & Co. KGaA	369
Currency effects and other changes	1,408
<b>Noncontrolling interests as of September 30, 2022</b>	<b>12,774</b>

## 17. FRESENIUS SE & CO. KGAA SHAREHOLDERS' EQUITY

### SUBSCRIBED CAPITAL

As of January 1, 2022, the subscribed capital of Fresenius SE & Co. KGaA consisted of 558,502,143 bearer ordinary shares.

On June 9, 2022, Fresenius SE & Co. KGaA successfully completed a capital increase in kind with subscription rights in return for the contribution of dividend entitlements as part of the share dividend. In connection with the capital increase, 4,735,134 new bearer ordinary shares were issued and the subscribed capital was increased by €4,735,134 to €563,237,277. The new shares will have full dividend entitlement for the fiscal year 2022; they are admitted to trading on the stock exchange.

During the first three quarters of 2022, no stock options were exercised. Consequently, as of September 30, 2022, the subscribed capital of Fresenius SE & Co. KGaA consisted of 563,237,277 bearer ordinary shares. The shares are issued as non-par value shares. The proportionate amount of the subscribed capital is €1.00 per share.

### AUTHORIZED CAPITAL

By resolution of the Annual General Meeting on May 13, 2022, the previous Authorized Capital I was revoked and a new Authorized Capital I (2022) was created.

Accordingly, the general partner, Fresenius Management SE, is authorized, with the approval of the Supervisory Board, until May 12, 2027, to increase Fresenius SE & Co. KGaA's share capital (subscribed capital) by a total amount of up to €125,000,000 through a single or multiple issues of new bearer ordinary shares against cash contributions and/or contributions in kind (Authorized Capital I (2022)). The number of shares must increase in the same proportion as the subscribed capital. In principle, shareholders must be granted a subscription right. In defined cases, the general partner is authorized, with the consent of the Supervisory Board, to decide on the exclusion of the shareholders' subscription right (e.g. to eliminate fractional amounts). For cash contributions, the authorization can only be exercised if the issue price is not significantly below the stock exchange price of the already listed shares at the time the issue price is fixed with final effect by the general partner. Furthermore, in case of a capital increase against cash contributions, the proportionate amount of the shares issued with exclusion of subscription rights may not

exceed 10% of the subscribed capital. An exclusion of subscription rights in the context of the use of other authorizations concerning the issuance or the sale of the shares of Fresenius SE & Co. KGaA or the issuance of rights which authorize or bind to the subscription of shares of Fresenius SE & Co. KGaA has to be taken into consideration during the duration of the Authorized Capital until its utilization. In the case of a subscription in kind, the subscription right can be excluded only in order to acquire a company, parts of a company or a participation in a company.

The authorizations granted concerning the exclusion of subscription rights can be used by Fresenius Management SE only to such extent that the proportional amount of the total number of shares issued with exclusion of the subscription rights does not exceed 10% of the subscribed capital. An exclusion of subscription rights in the context of the use of other authorizations concerning the issuance or the sale of the shares of Fresenius SE & Co. KGaA or the issuance of rights which authorize or bind to the subscription of shares of Fresenius SE & Co. KGaA has to be taken into consideration during the duration of the Authorized Capital until its utilization.

The changes to the Authorized Capital I became effective upon registration with the commercial register on July 5, 2022.

## CONDITIONAL CAPITAL

In order to fulfill the subscription rights under the current stock option plan 2013 of Fresenius SE & Co. KGaA, Conditional Capital IV exists (see note 23, Share-based compensation plans). Another Conditional Capital III exists for the authorization to issue option bearer bonds and/or convertible bonds.

This authorization from May 18, 2018 was revoked by resolution of the Annual General Meeting of Fresenius SE & Co. KGaA on May 13, 2022 and replaced by an identical new Conditional Capital III with a five-year term.

Accordingly, the general partner is authorized, with the approval of the Supervisory Board, until May 12, 2027, to issue option bearer bonds and/or convertible bearer bonds, once or several times, for a total nominal amount of up to €2.5 billion. To fulfill the granted subscription rights, the subscribed capital of Fresenius SE & Co. KGaA is increased conditionally by up to €48,971,202 through issuing of up to 48,971,202 new bearer ordinary shares. The conditional capital increase shall only be implemented to the extent that the holders of cash issued convertible bonds or of

cash issued warrants from option bonds exercise their conversion or option rights and as long as no other forms of settlement are used. The new bearer ordinary shares shall participate in the profits from the start of the fiscal year in which they are issued.

The new Conditional Capital III became effective upon registration with the commercial register on July 5, 2022.

The Conditional Capital did not change in the first three quarters of 2022. It was composed as follows as of September 30, 2022:

in €	Ordinary shares
Conditional Capital I Fresenius AG Stock Option Plan 2003 (expired)	4,735,083
Conditional Capital II Fresenius SE Stock Option Plan 2008 (expired)	3,452,937
Conditional Capital III option bearer bonds and/or convertible bonds	48,971,202
Conditional Capital IV Fresenius SE & Co. KGaA Stock Option Plan 2013	22,824,857
<b>Total Conditional Capital as of September 30, 2022</b>	<b>79,984,079</b>

## CAPITAL RESERVES

Capital reserves are comprised of the premium paid on the issue of shares and the exercise of stock options (additional paid-in capital).

In the first half of 2022, the capital reserves increased by €142 million in connection with the capital increase of the subscribed capital. The accrued expenses in an amount of €0.8 million were charged against the capital reserves.

## DIVIDENDS

Under the German Stock Corporation Act (AktG), the amount of dividends available for distribution to shareholders is based upon the unconsolidated retained earnings of Fresenius SE & Co. KGaA as reported in its statement of financial position determined in accordance with the German Commercial Code (HGB).

In May 2022, a dividend of €0.92 per bearer ordinary share was approved by Fresenius SE & Co. KGaA's shareholders at the Annual General Meeting. The total dividend was €514 million. The shareholders had the opportunity to exchange a portion of the dividend (Dividend Option Portion) for Fresenius SE & Co. KGaA shares. In June 2022, €147 million in dividend entitlements for new shares were distributed from authorized capital and therefore not substituted for cash. The remaining portion of the dividend in the amount of €367 million was paid in cash in June 2022.

## OTHER NOTES

### 18. LEGAL AND REGULATORY MATTERS

The Fresenius Group is routinely involved in claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Fresenius Group currently deems to be material or noteworthy are described below. The Fresenius Group records its litigation reserves for certain legal proceedings and regulatory matters to the extent that the Fresenius Group determines an unfavorable outcome is probable and the amount of loss can be reasonably estimated. For the other matters described below, the Fresenius Group believes that the loss is not probable and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with Fresenius Group's view of the merits can occur. The Fresenius Group believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.

Further information regarding legal disputes, court proceedings and investigations can be found in detail in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS. In the following, only changes as far as content or wording are concerned during the first three quarters ended September 30, 2022 compared to the information provided in the consolidated financial statements are described. These changes should be read in conjunction with the overall information in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS; defined terms or abbreviations having the same meaning as in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.

#### INTERNAL REVIEW /FCPA COMPLIANCE

Due in part to COVID-19 pandemic restrictions, the monitorship program faced certain delays, but FMC-AG & Co. KGaA is working to complete all its obligations under the resolution with the United States Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and expects the certification decision of the monitor by the end of 2022 and, if that decision is to certify, the formalization and publication of the end of the monitorship by the end of the first quarter of 2023.

#### CIVIL COMPLAINT "HAWAII"

On June 7, 2022, Fresenius Medical Care Holdings, Inc. (FMCH) and Hawaii entered into an agreement under which FMCH paid US\$13 million (€12 million) in restitution

and interest and all claims, counterclaims, and cross-claims raised by or against FMCH in any part of the litigation were extinguished.

#### SUBPOENAS "COLORADO AND NEW YORK"

FMCH cooperated in the Denver USAO investigation, which FMCH understands had concluded on or before June 1, 2022.

#### SUBPOENA "FRESENIUS VASCULAR CARE" (AAC)

FMCH cooperated in the Brooklyn investigation, which was understood to be separate and distinct from settlements entered in 2015 in Connecticut, Florida and Rhode Island of allegations against American Access Care LLC (AAC) following FMCH's 2011 acquisition of AAC.

On July 12, 2022, after the Court denied the USAO's motions to renew the sealing of the relators' complaint, the USAO filed a complaint-in-intervention. United States ex rel. Pepe and Sherman v. Fresenius Vascular Care, Inc. et al, 1:14-cv-3505. The United States' and relators' complaints allege that the defendants billed and received government payment for surgery that was not medically necessary. FMCH expects to defend the allegations asserted in the litigation now proceeding.

#### SUBPOENA "NEW YORK" (SHIEL)

On June 14, 2022, the Brooklyn USAO declined to intervene on two anonymous relator complaints that underlay the investigation. The relators, who remain anonymous, are proceeding with litigation at their own expense against both Shiel and FMCH entities, alleging that the defendants

wrongly caused government payers to pay for laboratory tests that were falsely or improperly invoiced and retaliated against relators for objecting to the alleged misconduct. Relator v. Shiel Medical Laboratory, 1:16-cv-01090 (E.D.N.Y. 2016); Relator v. Shiel Holdings, 1:17-cv-02732 (E.D.N.Y. 2017). FMCH will defend allegations directed against entities it controls .

#### **VIFOR PATENT INFRINGEMENT FRESENIUS MEDICAL CARE (DELAWARE)**

In relation to the remaining pending cases and the defendant Teva, trial took place for the first complaint between January 19 and 22, 2021. Another patent newly listed in the Orange Book was added to the second complaint on June 23, 2021. Trial was scheduled for the second complaint for late June 2022, but was cancelled on June 14, 2022. By final judgement dated August 25, 2022, the Court decided for the first complaint that the generic product proposed in Teva's ANDA infringes the patent claims subject to the complaint and that such patent claims are valid. Further, unless the order is overturned or the parties agree otherwise, the effective date of any final approval by the FDA for Teva's ANDA shall not be a date until the underlying patent, including any pediatric extension, expires. On September 21, 2022, Teva filed an appeal to the U.S. Court of Appeals for the Federal Circuit to contest the first instance court decision. Also on September 21, 2022, VFMCRP filed another complaint for patent infringement against Teva in the U.S. District Court for the District of Delaware (Case

No. 1:22-cv-01227-MN, third complaint) in response to the company's ANDA for generic versions of Velphoro® and on the basis of another newly listed patent in the Orange Book. On October 4, 2022, a motion to stay the proceedings of the second complaint until the appeal for the first complaint is resolved was granted by the first instance Court.

#### **HBDI REQUEST**

In February 2022, FMC-AG & Co. KGaA received a formal request for information from the Hessen Data Protection Authority (Hessischer Beauftragter für Datenschutz und Informationsfreiheit or HBDI). The information request relates to specific data processing functions of a few of FMC-AG & Co. KGaA's peritoneal dialysis devices. FMC-AG & Co. KGaA is committed to comply with the HBDI's request and cooperate with them, and it is working to provide the relevant information.

#### **OSHA COMPLAINT**

On March 20 and April 12, 2022, respectively, an attorney employed as general counsel for FMC-AG & Co. KGaA's North American division from 2013 to 2016 filed a complaint with the Occupational Safety and Health Administration (OSHA) under the Sarbanes-Oxley Act of 2002 and other anti-retaliation statutes, and a civil lawsuit in Suffolk County, Massachusetts seeking compensation for personnel management decisions allegedly adverse to him. OSHA Case No. 1-076-22-049; Kott v. National Medical Care, Inc., Case No. 22-802 (Superior Court, Suffolk County, Mass.)

The plaintiff alleges in support of his demands for compensation that he was transferred to a subordinate position in the global legal department, and subsequently terminated from employment as part of the FME25 reorganization, in retaliation for legal advice he provided with respect to a licensing agreement with DaVita relating to pharmaceutical operations and products. The DaVita licensing agreement expired by its terms in 2017.

As previously disclosed in FMC-AG & Co. KGaA's financial statements, the United States Department of Justice has reviewed multiple aspects of the DaVita contract in question, including those relevant to the plaintiff's allegations. No enforcement action has resulted against FMC-AG & Co. KGaA.

Other bases of retaliation alleged by the plaintiff implicate internal personnel and privacy protection concerns that do not impact ongoing operations, and on which FMC-AG & Co. KGaA does not comment.

#### **GENERAL RISKS**

On April 21, 2022, Fresenius Medical Care Holdings, Inc. (FMCH) paused shipping of new dialysis machines in the United States at the recommendation of the FDA following FMCH's voluntary report of a potential bio-compatibility concern. The concern arose from a component that was already scheduled to be replaced later in 2022. As of October 28, 2022, FMCH received clearance from the FDA encompassing the replacement component and resumed shipping machines.

## 19. FINANCIAL INSTRUMENTS

### VALUATION OF FINANCIAL INSTRUMENTS

#### Carrying amounts of financial instruments

As of September 30, 2022 and December 31, 2021, the carrying amounts of financial instruments by item of the statement of financial position and structured according to categories were as follows:

€ in millions	September 30, 2022						
	Carrying amount	Amortized cost	Fair value through profit and loss <sup>1</sup>	Fair value through other comprehensive income <sup>2</sup>	Relating to no category		
					Derivatives designated as cash flow hedging instruments at fair value	Put option liabilities measured at fair value	Valuation according to IFRS 16 for leasing receivables and liabilities
<b>Financial assets</b>							
Cash and cash equivalents	2,128	1,845	283				
Trade accounts and other receivables, less allowances for expected credit losses	7,977	7,792	93	1			91
Accounts receivable from and loans to related parties	169	169					
Other financial assets <sup>3</sup>	2,978	2,055	307	453	31		132
<b>Financial assets</b>	<b>13,252</b>	<b>11,861</b>	<b>683</b>	<b>454</b>	<b>31</b>	<b>–</b>	<b>223</b>
<b>Financial liabilities</b>							
Trade accounts payable	1,926	1,926					
Short-term accounts payable to related parties	71	71					
Short-term debt	1,608	1,608					
Short-term debt from related parties	11	11					
Long-term debt	2,871	2,871					
Lease liabilities	7,041						7,041
Bonds	16,588	16,588					
Convertible bonds	488	488					
Other financial liabilities <sup>4</sup>	5,802	2,891	718		18	2,175	
<b>Financial liabilities</b>	<b>36,406</b>	<b>26,454</b>	<b>718</b>	<b>–</b>	<b>18</b>	<b>2,175</b>	<b>7,041</b>

<sup>1</sup> All included financial assets and liabilities are mandatorily measured at fair value through profit and loss according to IFRS 9.

<sup>2</sup> The option to measure equity instruments at fair value through other comprehensive income has been exercised. The option has been used for €94 million other investments (included in other financial assets).

<sup>3</sup> Other financial assets are included in the item other current and non-current assets in the consolidated statement of financial position.

<sup>4</sup> Other financial liabilities are included in the items short-term provisions and other short-term liabilities and long-term provisions and other long-term liabilities in the consolidated statement of financial position.

December 31, 2021							
€ in millions	Carrying amount	Amortized cost	Fair value through profit and loss <sup>1</sup>	Fair value through other comprehensive income <sup>2</sup>	Relating to no category		
					Derivatives designated as cash flow hedging instruments at fair value	Put option liabilities measured at fair value	Valuation according to IFRS 16 for leasing receivables and liabilities
<b>Financial assets</b>							
Cash and cash equivalents	2,764	1,936	828				
Trade accounts and other receivables, less allowances for expected credit losses	7,045	6,822	108	34			81
Accounts receivable from and loans to related parties	147	147					
Other financial assets <sup>3</sup>	2,560	1,667	342	412	8		131
<b>Financial assets</b>	<b>12,516</b>	<b>10,572</b>	<b>1,278</b>	<b>446</b>	<b>8</b>	<b>–</b>	<b>212</b>
<b>Financial liabilities</b>							
Trade accounts payable	2,039	2,039					
Short-term accounts payable to related parties	92	92					
Short-term debt	2,841	2,841					
Short-term debt from related parties	8	8					
Long-term debt	2,600	2,600					
Lease liabilities	6,590						6,590
Bonds	14,634	14,634					
Convertible bonds	482	482					
Other financial liabilities <sup>4</sup>	4,026	2,407	557		18	1,044	
<b>Financial liabilities</b>	<b>33,312</b>	<b>25,103</b>	<b>557</b>	<b>–</b>	<b>18</b>	<b>1,044</b>	<b>6,590</b>

<sup>1</sup> All included financial assets and liabilities are mandatorily measured at fair value through profit and loss according to IFRS 9.

<sup>2</sup> The option to measure equity instruments at fair value through other comprehensive income has been exercised. The option has been used for €85 million other investments (included in other financial assets).

<sup>3</sup> Other financial assets are included in the item other current and non-current assets in the consolidated statement of financial position.

<sup>4</sup> Other financial liabilities are included in the items short-term provisions and other short-term liabilities and long-term provisions and other long-term liabilities in the consolidated statement of financial position.

## Fair value of financial instruments

The following table shows the carrying amounts and the fair value hierarchy levels as of September 30, 2022 and December 31, 2021:

€ in millions	September 30, 2022				December 31, 2021			
	Carrying amount	Fair value			Carrying amount	Fair value		
		Level 1	Level 2	Level 3		Level 1	Level 2	Level 3
<b>Financial assets</b>								
Cash and cash equivalents <sup>1</sup>	283	283			828	828		
Trade accounts and other receivables, less allowances for expected credit losses <sup>1</sup>	94		94		142		142	
Other financial assets <sup>1</sup>								
Debt instruments	468	463	5		422	418	4	
Equity investments	266	61	114	91	320	122	105	93
Derivatives designated as cash flow hedging instruments	31		31		8		8	
Derivatives not designated as hedging instruments	26		26		12		12	
<b>Financial liabilities</b>								
Long-term debt	2,871		2,813		2,600		2,626	
Bonds	16,588	14,574			14,634	15,201		
Convertible bonds	488	479			482	499		
Other financial liabilities <sup>1</sup>								
Put option liabilities	2,175			2,175	1,044			1,044
Accrued contingent payments outstanding for acquisitions	680			680	528			528
Derivatives designated as cash flow hedging instruments	18		18		18		18	
Derivatives not designated as hedging instruments	38		38		29		29	

<sup>1</sup> Fair value information is not provided for financial instruments, if the carrying amount is a reasonable estimate of the fair value due to the relatively short period of maturity of these instruments.

The increase of put option liabilities relates to the acquisition of mAbxience and InterWell Health. These put option liabilities are classified as level 3.

Explanations regarding the significant methods and assumptions used to estimate the fair values of financial

instruments and classification of fair value measurements according to the three-tier fair value hierarchy as well as explanations with regard to existing and expected risks

from financial instruments and hedging can be found in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.



The following table shows the changes of the fair values of financial instruments classified as level 3 in the first three quarters of 2022:

€ in millions	Equity investments	Accrued contingent payments outstanding for acquisitions	Put option liabilities
<b>As of January 1, 2022</b>	<b>93</b>	<b>528</b>	<b>1,044</b>
Additions	2	180	1,102
Disposals	-	-27	-7
Gain/loss recognized in profit or loss	-11	-7	0
Gain/loss recognized in equity	-	-	-129
Currency effects and other changes	7	6	165
<b>As of September 30, 2022</b>	<b>91</b>	<b>680</b>	<b>2,175</b>

## 20. INFORMATION ON CAPITAL MANAGEMENT

The Fresenius Group has a solid financial profile. As of September 30, 2022, the equity ratio was 42.5% and the debt ratio (debt/total assets) was 35.6%. As of September 30, 2022, the leverage ratio (before special items) on the basis of net debt/EBITDA, calculated on the basis of closing rates, was 3.86 (December 31, 2021: 3.55).

The aims of the capital management and further information can be found in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.

The Fresenius Group is covered by the rating agencies Moody's, Standard & Poor's and Fitch.

The following table shows the company rating of Fresenius SE & Co. KGaA:

	Sept. 30, 2022	Dec. 31, 2021
<b>Standard &amp; Poor's</b>		
Corporate Credit Rating	BBB	BBB
Outlook	stable	stable
<b>Moody's</b>		
Corporate Credit Rating	Baa3	Baa3
Outlook	stable	stable
<b>Fitch</b>		
Corporate Credit Rating	BBB-	BBB-
Outlook	stable	stable

## 21. SUPPLEMENTARY INFORMATION ON THE CONSOLIDATED STATEMENT OF CASH FLOWS

In June 2022, dividend entitlements of Fresenius SE & Co. KGaA's shareholders in the amount of €147 million were not serviced in cash, but substituted for new shares from authorized capital (see note 17, Fresenius SE & Co. KGaA shareholders' equity). The cash settlement of the dividend entitlements of Fresenius SE & Co. KGaA's shareholders amounted to €367 million and is shown within net cash used in financing activities.

## 22. NOTES ON THE CONSOLIDATED SEGMENT REPORTING

### GENERAL

The consolidated segment reporting tables shown on pages 40 to 41 of this interim report are an integral part of the notes.

The Fresenius Group has identified the business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which corresponds to the internal organizational and reporting structures (Management Approach) at September 30, 2022.

The column Corporate is comprised of the holding functions of Fresenius SE & Co. KGaA as well as Fresenius Digital Technology GmbH, which provides services in the field of information technology. Corporate includes intersegment consolidation adjustments as well as all special items (see note 3, Special items).

The business segments were identified in accordance with IFRS 8, Operating Segments, which defines the segment reporting requirements in the annual financial statements and interim reports with regard to the operating business, product and service businesses and regions. Further explanations with regard to the business segments can be found in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.

## NOTES ON THE BUSINESS SEGMENTS

Explanations regarding the notes on the business segments can be found in the consolidated financial statements as of December 31, 2021 applying Section 315e HGB in accordance with IFRS.

### RECONCILIATION OF KEY FIGURES TO CONSOLIDATED EARNINGS

€ in millions	Q1-3/2022	Q1-3/2021
Total EBIT of reporting segments	3,026	3,120
Special items	-374	-51
General corporate expenses Corporate (EBIT)	-18	-34
<b>Group EBIT</b>	<b>2,634</b>	<b>3,035</b>
Net interest	-375	-384
<b>Income before income taxes</b>	<b>2,259</b>	<b>2,651</b>

### RECONCILIATION OF NET DEBT WITH THE CONSOLIDATED STATEMENT OF FINANCIAL POSITION

€ in millions	Sept. 30, 2022	Dec. 31, 2021
Short-term debt	1,608	2,841
Short-term debt from related parties	11	8
Current portion of long-term debt	528	473
Current portion of lease liabilities	911	832
Current portion of bonds	308	618
Long-term debt, less current portion	2,343	2,127
Lease liabilities, less current portion	6,130	5,758
Bonds, less current portion	16,280	14,016
Convertible bonds	488	482
<b>Debt</b>	<b>28,607</b>	<b>27,155</b>
less cash and cash equivalents	2,128	2,764
<b>Net debt</b>	<b>26,479</b>	<b>24,391</b>

## 23. SHARE-BASED COMPENSATION PLANS

### SHARE-BASED COMPENSATION PLANS OF FRESENIUS SE & CO. KGaA

As of September 30, 2022, Fresenius SE & Co. KGaA had two share-based compensation plans in place: the Fresenius SE & Co. KGaA Long Term Incentive Program 2013 (2013 LTIP) which is based on stock options and phantom stocks and the Long Term Incentive Plan 2018 (LTIP 2018) which is solely based on performance shares. Currently, solely LTIP 2018 can be used to grant performance shares.

### Transactions during the first three quarters of 2022

On September 12, 2022, Fresenius SE & Co. KGaA awarded 1,509,617 performance shares under the LTIP 2018, the total fair value at the grant date being €40 million, including 328,818 performance shares or €9 million awarded to the members of the Management Board of Fresenius Management SE. The fair value per performance share at the grant date was €26.30.

During the first three quarters of 2022, no stock options were exercised.

At September 30, 2022, 3,669,714 stock options issued under the 2013 LTIP were outstanding and exercisable. The members of the Fresenius Management SE Management Board held 461,250 stock options. At September 30, 2022, the Management Board members of Fresenius Management SE held 744,095 performance shares and employees of Fresenius SE & Co. KGaA held 3,042,996 performance shares under the LTIP 2018.

### SHARE-BASED COMPENSATION PLANS OF FRESENIUS MEDICAL CARE AG & CO. KGAA

On July 25, 2022, 1,673,865 performance shares with a total fair value of €68 million were allocated under the Fresenius Medical Care AG & Co. KGaA Long-Term Incentive Plan 2022+. At the time of allocation, the fair value per performance share was €40.46.

On March 1, 2022, 220,311 performance shares with a total fair value of €12 million were allocated under the Management Board Long Term Incentive Plan 2020 to the members of the Management Board and to senior members of Fresenius Medical Care AG & Co. KGaA's managerial staff who serve on Fresenius Medical Care AG & Co. KGaA's Executive Committee (Executive Committee). Of this number, 160,668 performance shares with a total fair value of €8 million relate to members of the Management Board and 59,643 performance shares with a total fair value of €3 million relate to members of the Executive Committee. These amounts will be amortized over the three-year

vesting period. The weighted average fair value per performance share at the allocation date was €52.58.

During the first three quarters of 2022, 409,110 stock options were exercised. Fresenius Medical Care AG & Co. KGaA received cash of €20.4 million upon exercise of these stock options.

### 24. SUBSEQUENT EVENTS

October 2022 was characterized worldwide by a regionally varying development of the COVID-19 pandemic with continuing high infection numbers and associated shortage of resources. The further development of the global situation and its impact on Fresenius remain uncertain.

Russia's ongoing war against Ukraine and the associated price increases, especially for energy, raw materials, and transport, will continue to have a direct and indirect

negative impact on the business activities of the Fresenius Group, which cannot be estimated at present.

The development of personnel costs and the disruption of supply chains also remain issues on a global level. Their impact on Fresenius will be continuously analyzed in detail.

Beyond that, there have been no significant changes in the Fresenius Group's operating environment following the end of the first three quarters of 2022. No other events of material importance on the assets and liabilities, financial position, and results of operations of the Group have occurred following the end of the first three quarters of 2022.

### 25. CORPORATE GOVERNANCE

For each consolidated stock exchange listed entity, the declaration pursuant to Section 161 of the German Stock Corporation Act (Aktiengesetz) has been issued and made available to shareholders on the website of Fresenius SE & Co. KGaA ([www.fresenius.com/corporate-governance](http://www.fresenius.com/corporate-governance)), and of Fresenius Medical Care AG & Co. KGaA ([www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com)).

## FINANCIAL CALENDAR

Report on FY/22 Conference call, Live webcast	February 22, 2023
Report on 1st quarter 2023 Conference call, Live webcast	May 9, 2023
Annual General Meeting	May 17, 2023
Report on 1st half 2023 Conference call, Live webcast	August 2, 2023
Report on 1st – 3rd quarter 2023 Conference call, Live webcast	November 2, 2023

Subject to change

## FRESENIUS SHARE/ADR

	Ordinary share		ADR
Securities identification no.	578 560	CUSIP	35804M105
Ticker symbol	FRE	Ticker symbol	FSNUY
ISIN	DE0005785604	ISIN	US35804M1053
Bloomberg symbol	FRE GR	Structure	Sponsored Level 1 ADR
Reuters symbol	FREG.de	Ratio	4 ADR = 1 share
Main trading location	Frankfurt / Xetra	Trading platform	OTC

## CONTACT

### Corporate Headquarters

Else-Kröner-Straße 1  
Bad Homburg v. d. H.  
Germany

### Postal address

Fresenius SE & Co. KGaA  
61346 Bad Homburg v. d. H.  
Germany

### Contact for shareholders

Investor Relations & Sustainability  
Telephone: ++ 49 61 72 6 08-24 87  
Telefax: ++ 49 61 72 6 08-24 88  
E-Mail: ir-fre@fresenius.com

### Contact for journalists

Corporate Communications  
Telephone: ++ 49 61 72 6 08-23 02  
Telefax: ++ 49 61 72 6 08-22 94  
E-mail: pr-fre@fresenius.com

Commercial Register: Bad Homburg v. d. H.; HRB 11852  
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE  
Registered Office and Commercial Register: Bad Homburg v. d. H.; HRB 11673  
Management Board: Michael Sen (President and CEO), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Sara Hennicken, Dr. Carla Kriwet, Dr. Ernst Wastler  
Chairman of the Supervisory Board: Wolfgang Kirsch

For additional information on the performance indicators used please refer to our website <https://www.fresenius.com/alternative-performance-measures>.

**Forward-looking statements:**

This Quarterly Financial Report contains forward-looking statements. These statements represent assessments which we have made on the basis of the information available to us at the time. Should the assumptions on which the statements are based on not occur, or if risks should arise – as mentioned in the consolidated financial statements and the management report as of December 31, 2021 applying Section 315e HBG in accordance with IFRS and the SEC filings of Fresenius Medical Care AG & Co. KGaA – the actual results could differ materially from the results currently expected.

